¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G³¯¤p©ú10152293 |
µoªí®É¶¡:2022/6/11 ¤U¤È 05:47:24
²Ä 5383 ½g¦^À³
|
½Ð°Ý¦U¦ì¤j¤j ¨È·à±d2B¸ÕÅ礵¦~©³«e¡A¦³»¡·|¤½¥¬´Á¤¤¼Æ¾Ú¶Ü ¦n¹³¬O»¡©ú¦~¤W¥b¦~§¹¦¨2B¸ÕÅç¸Ñª¼ |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G©t¨àÃÄ10140658 |
µoªí®É¶¡:2022/6/11 ¤U¤È 04:25:41
²Ä 5382 ½g¦^À³
|
³Ì·s²³ø²Ä16¶³oÓ·sÅçÃÒªº¾÷Âà«D±`¤£¿ù¡A¤U¥b¦~§Æ±æ¦Ñ·à2B¸ÕÅ縨¹ê¯f¤Hªº¬D¿ï¡A¬ß±æ¦~©³´N¯à¦³¥¿¦Vªº´Á¤¤¼Æ¾Ú~¥[ªo°Ú |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G©t¨àÃÄ10140658 |
µoªí®É¶¡:2022/6/10 ¤U¤È 03:23:51
²Ä 5381 ½g¦^À³
|
To:ª©¥D¤j¤H
½Ð±N¥H¤U³sµ²¼W¥[¨ì¼ÐÃD¡AÁÂÁ±z! 2022.06²³ø-ir.aslanpharma.com/static-files/1c525489-d209-42c4-af7e-992f23c4251c |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G«Ó°¶10144972 |
µoªí®É¶¡:2022/6/9 ¤U¤È 11:47:24
²Ä 5380 ½g¦^À³
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2022/6/9 ¤U¤È 11:00:16
²Ä 5379 ½g¦^À³
|
¥xÁÞ¤j¡A
¬Q¤Ñ±ß¤W ASLN CEO ¨ü¨é°Ó JEFFERIES ÁܽСA°Ý¡Aµª 26¤ÀÄÁ¡C ºë±mµ´Û¡I ¥i¤Wºô¥h¬Ý¬Ý¡C
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2022/6/8 ¤U¤È 10:49:30²Ä 5371 ½g¦^À³ ASLAN PHARMACEUTICALS TO PARTICIPATE IN FIRESIDE CHAT AT JEFFERIES GLOBAL HEALTHCARE CONFERENCE Menlo Park, California, and Singapore, May 31, 2022, ¡V ASLAN Pharmaceuticals (Nasdaq:ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced that Dr Carl Firth, CEO, will participate in a fireside chat at the Jefferies Global Healthcare Conference. The conference will be held in-person in New York, NY, June 8 - 10, 2022. Management will be available for virtual one-on-one meetings throughout the conference. Fireside Chat details Date: Wednesday, June 8, 2022 Time: 10:00am ET Track: 9 Webcast link: Click here to listen in live or via replay aslanpharma.com/app/uploads/2022/05/ASLAN-Pharmaceuticals-to-Participate-in-Fireside-Chat-at-Jefferies-Global-Healthcare-Conference.pdf
CEO ¨ü³X¡GASLAN004 2b ¥u·|¿ï¾Ü¶Ç²ÎAD±wªÌ¨Ó°Ñ¥[Á{§É¡A¥HÅçÃÒ¹F1b±Ó·P«×¤À§é¤¤ªºEASI75ªº69%ªºÀø®Ä¡C
¥t¥~2b 16¶gªºÀøµ{Àø®Ä·|¤ñ1b ¶È8¶gªvÀøªºÀø®ÄÁÙÀu¡C
´£¨ìAD¦³80%·|²£¥Íý³Ý⋯⋯¨Öµo¯g¤§¦X¨ÖªvÀø¡AASLAN004¥ç¦³Àu¶Õ¡C
Àø®Ä¤ÎªvÀø¦¨¥»¥²¶·Àu©óDupilumab AD¡A¤~¯à¦³Ävª§¤O¦b¤@缐¥«³õ¤W·í¥t¤@ºØ¿ï¾Ü¡C
¥H¤W«ÂI⋯⋯^¤å聴¤O¦³¡A¶È¨Ñ°Ñ¦Ò¡C |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¥xÁÞ10138776 |
µoªí®É¶¡:2022/6/9 ¤U¤È 10:50:37
²Ä 5378 ½g¦^À³
|
¨S¦³¤°»ò§Q¦h´N¦¨¥æ¦Ê¸UªÑ¡A¥þ¶R¥þ±½¡A·Pı°Ê§@¦³ÂI«æ¡A¨ì©³¦b«æ¤°»ò¡H |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2022/6/9 ¤U¤È 05:10:27
²Ä 5377 ½g¦^À³
|
ASLAN004 2B ,¨Ìç°£§CTRAC²Õ/§CIgE/§C¶Ý»Ä²ÓM/µL¨Öµo¯g «D¶Ç²Î¤¤-««×AD±wªÌ.
EASI75(¦©°£¹ï·Ó²Õ)Àø®Ä PK ¼ÒÀÀ
ASLAN004 54%(1b RITT--69%-15%=54%) VS Dupilumab 28%~32% (¤T´Á2ÓÁ{§É,¤¤/°ªTRAC²Õ)
ASLAN004 AD ¤j´T»â¥ýDupilumab EASI75Àø®Äªñ70%~90%,¥§¡Àu80%ÁͶÕ(54%/30%=180%)¡I
³oºØÀø®Ä®t²§ASLN³Q¨ÖÁÊ»ù¤~·|°ª! |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¸Ø±i10133098 |
µoªí®É¶¡:2022/6/9 ¤U¤È 12:28:42
²Ä 5376 ½g¦^À³
|
ÅÞ¿è«ä¦Ò.......
CEO¤w¸g¦³Á¿¨ì......ªvÀø¦¨¥»¥²¶·Àu©óDupilumab AD¡A¤~¯à¦³Ävª§¤O¦b¤@缐¥«³õ¤W·í¥t¤@ºØ¿ï¾Ü......... ¤w¸g¦bÁ¿¦¨¥»°ÝÃD¤F......... ¬Ý¨ÓÀø®Ä¤è±~~~CEO¤w¸g½T»{¬°¥¿¦V¤F...... ¨È·à±dŤF(µ¥³Q¨Ö)..... |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡GDHL10147526 |
µoªí®É¶¡:2022/6/9 ¤U¤È 12:16:30
²Ä 5375 ½g¦^À³
|
¬Ý¨Ó¦p¦ó¿z¯f¤H¬O¦¨¥\ªºÃöÁä¡I ¥[ªo¡I Ä~Äò¬Ý¤U¥h¡I |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2022/6/9 ¤W¤È 10:23:23
²Ä 5374 ½g¦^À³
|
Äò¡A----§ó¥¿1
°Ý:¦p¦ó°Ï¤À«D¶Ç²ÎAD±wªÌ¡H¦h¤Ö¤ñ²v¡H
µª:IgE,TRAC,¶Ý»Ä©Ê细M¡A¬O§_¦³¨Öµo¯gµ¥¨Ó°Ï¤À«D¶Ç²ÎAD±wªÌ¡C
«D¶Ç²ÎAD±wªÌ¤ñ²v¤j约10%~15%¡C |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2022/6/9 ¤W¤È 07:35:51
²Ä 5373 ½g¦^À³
|
6¤ë¤½¥q²¤¶¡A¥XÄl ASLAN003 ¥¿¦b¬ã¨s ¥Õ·µ·(¥Ö½§¥Õ¤Æ)¡A秃¾v¯g¦Û¡AÅé§K¬Ì¯e¯f¡A约 3%¬ü°ê¤H±w¯f¡C
©|µLFDA®Öã¥ÎÃÄ¡C |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2022/6/9 ¤W¤È 06:41:35
²Ä 5372 ½g¦^À³
|
Äò¡A
°Ý:¦p¦ó°Ï¤À«D¶Ç²ÎAD±wªÌ¡H¦h¤Ö¤ñ²v¡H
µª:IgE,TRAC,¶Ý»Ä©Ê细M¡A¬O§_¦³¨Öµo¯gµ¥¨Ó°Ï¤À«D¶Ç²ÎAD±wªÌ¡C
«D¶Ç²ÎAD±wªÌ¤ñ²v¤j约10%¡C |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2022/6/8 ¤U¤È 10:49:30
²Ä 5371 ½g¦^À³
|
ASLAN PHARMACEUTICALS TO PARTICIPATE IN FIRESIDE CHAT AT JEFFERIES GLOBAL HEALTHCARE CONFERENCE Menlo Park, California, and Singapore, May 31, 2022, ¡V ASLAN Pharmaceuticals (Nasdaq:ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced that Dr Carl Firth, CEO, will participate in a fireside chat at the Jefferies Global Healthcare Conference. The conference will be held in-person in New York, NY, June 8 - 10, 2022. Management will be available for virtual one-on-one meetings throughout the conference. Fireside Chat details Date: Wednesday, June 8, 2022 Time: 10:00am ET Track: 9 Webcast link: Click here to listen in live or via replay aslanpharma.com/app/uploads/2022/05/ASLAN-Pharmaceuticals-to-Participate-in-Fireside-Chat-at-Jefferies-Global-Healthcare-Conference.pdf
CEO ¨ü³X¡GASLAN004 2b ¥u·|¿ï¾Ü¶Ç²ÎAD±wªÌ¨Ó°Ñ¥[Á{§É¡A¥HÅçÃÒ¹F1b±Ó·P«×¤À§é¤¤ªºEASI75ªº69%ªºÀø®Ä¡C
¥t¥~2b 16¶gªºÀøµ{Àø®Ä·|¤ñ1b ¶È8¶gªvÀøªºÀø®ÄÁÙÀu¡C
´£¨ìAD¦³80%·|²£¥Íý³Ý⋯⋯¨Öµo¯g¤§¦X¨ÖªvÀø¡AASLAN004¥ç¦³Àu¶Õ¡C
Àø®Ä¤ÎªvÀø¦¨¥»¥²¶·Àu©óDupilumab AD¡A¤~¯à¦³Ävª§¤O¦b¤@缐¥«³õ¤W·í¥t¤@ºØ¿ï¾Ü¡C
¥H¤W«ÂI⋯⋯^¤å聴¤O¦³¡A¶È¨Ñ°Ñ¦Ò¡C
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2022/6/7 ¤U¤È 07:30:14
²Ä 5370 ½g¦^À³
|
¥[§QºÖ¥§亚¦{门¬¥©¬§J©M·s¥[©Y¡A2022¦~6¤ë7¤é¡]GLOBE NEWSWIRE¡^ -- ASLAN Pharmaceuticals¡]纳´µ达§J¡^¤½¥q¡]NASDAQ¡^¬O¬ü国ªº¤@®a¨î药¤½¥q¡C ©M·s¥[©Y¡A2022¦~6¤ë7¤é (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (NASDAQ: ASLN¡^¬O¤@®a¥H§K¬Ì学为«点ªº临§É阶¬qªº¥Íª«¨î药¤½¥q¡A¥¿¦b开发§ï变±wªÌ¥Í¬¡ªº创·s疗ªk¡A ¤µ¤Ñ该¤½¥q«Å¥¬ÉO约¿«ÀN´¶ª÷´µ¤j学医学°|ªºShawn Kwatra³Õ¤h¡]§@为顾问¡^©M§ù§J¤j学医学¤¤¤ßªºMadan Kwatra³Õ¤h开®i¬ã¨s¦X§@¡A¬ã¨sIL-13Ra1亚单¦ì¦b2«¬¤¶¾Éªºª¢¯g©Ê¯e¯f¡A¯S别¬O¯SÀ³©Ê¥Öª¢¡]AD¡^¤¤ªº¿W¯S§@¥Î¡A³oÉO¨ä¥L³~径¦¨¤Àªº§@¥Î¤£¦P¡C
¸Ó¬ã¨s¦X§@将评¦ôIL-13Ra1¦b¤¤«×¦Ü««×AD±wªÌý©¥»¤¤ªº§@¥Î¡A¦}将测试IL-13Ra1¤¶导ªº过±Ó¡Bª¢¯g©M调节³~径¦p¦ó¨ü¨ìeblasakimab对2«¬¨üÊ^ªº¿ï¾Ü©Ê¹v¦V¼v响¡AÉO¥Ø«e护²z标㤤对1«¬©M2«¬¨üÊ^ªºÆΪxªý断§Î¦¨对¤ñ¡C这¨Ç¬ã¨s还将±´¯Áeblasakimab专门针对IL-13Ra1ªº¤U´å®Ä应¡A¦}¦³§U¤_进¤@¨B¤F¸ÑIL-4©MIL-13«H号传导ªº¥Íª«¬ÛÃö©Ê¡C¦X§@ªºªì¨B结ªG将¦b2022¦~¤U¥b¦~©ÜÅSµoªí¡C
Shawn Kwatra¡A医学³Õ¤h¡A¬O马¨½兰¦{¤Úûتº¼¯¥«约¿«ÀN´¶ª÷´µ¤j学医学°|ªº¥Ö肤¬ì°Æ±Ð±Â¡A¤]¬O约¿«ÀN´¶ª÷´µæ±Ö}¤¤¤ßªº¥D¥ô¡C¥Lªº临§É专业领°ì¥]¬A¯S应©Ê¥Öª¢¡BºC©Êæ±Ö}¯g¡B结节©Êæ±Ö}¯g©M¥Á±Ú¥Ö肤ªº¥Ö肤¯f学¡CKwatra³Õ¤h¬O180¦h¥÷¥Xª©ª«ªº§@ªÌ©Î¦XµÛªÌ¡A¦}¥B¬O¦³¦â¤HÏú¥Ö肤协会ªº¸³¨Æ会¦¨员¡C
Madan Kwatra³Õ¤h¬O§ù§J¤j学医学¤¤¤ß³Â¾K学¨t¤À¤l药²z学实验«Çªº¥D¥ô¡CKwatra³Õ¤h¬O¤@¦ì¨üÊ^药²z学®a¡A´¿ÉO诺贝ûØ奖±o¥DBob Lefkowitz³Õ¤h¤@°_±µ¨ü°ö训¡C
约¿«ÀN´¶ª÷´µ¤j学医学°|¥Ö肤¯f学°Æ±Ð±ÂShawn Kwatra³Õ¤h评论说¡G 现¦b¬O¯S应©Ê¥Öª¢ªº¤@个¥O¤H¹ª»Rªº时´Á¡A¦UÏú·s«¬疗ªk¥¿¦b¥X现¡C为¤F§ïµ½±wªÌªºªv疗选择¡A«nªº¬O¶°¤¤ºë¤O获±o对¤£¦Pªv疗组©Ò针对ªº¯S©w¯e¯fÉó¨îªº§@¥Îªº§ó¦n²z¸Ñ¡A¦p调节IL-4©MIL-13«H号ªº1«¬©M2«¬¨üÊ^Î`¦Xª«ªº¦UÏú¦¨¤À¡C
±q银®h¯fªº¶i®i¤¤¡A§Ú们¤F¸Ñ¨ì¡A针对¦@¦Pªº¤À¤l³q¸ô¤¤ªº¤£¦P亚°ò¥i¥H产¥ÍºIµM¤£¦PªºÁ{§É®ÄªG¡C§Ú们§Æ±æ这项¬ã¨s¦³¥i¯à¼á²M1«¬©M2«¬¨üÅé¤Î¨ä¦¨¤À¦bÅX°ÊADµo¯f¾÷¨î¤¤ªº¤£¦P§@¥Î¡C
ASLAN¨îÃĤ½¥qÂà¤Æ¬ì¾Ç¥DºÞFerda Cevikbas³Õ¤hµû½×说¡G ³o项¦X§@将ûñ§U§Ú们¤F¸ÑIL-13Ra1«H号¶Ç¾É¦bAD¤¤ªº¿W¯S§@¥Î¡A¨Ö¬°eblasakimabÉO¨ä¥L³~径¯S²§©ÊªvÀøªº®t²§¤Æ´£¨Ñ¾÷¨î°ò¦¡C§Ú们´Á«ÝþÓÉOShawn Kwatra³Õ¤h©MMadan Kwatra³Õ¤h¦X§@¡A¥H产¥Í¬}¹î¤O¡A§iª¾IL-13¬ÛÃö³~径ªº¤À¤Æ¹v¦VªvÀø¦p¦ó¨Ï©|¥¼±q这ºØºC©Ê¯e¯f¤¤§ä¨ìºþ¸ÑªºAD±wªÌ¨ü¯q¡C
MENLO PARK, Calif. and SINGAPORE, June 07, 2022 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (NASDAQ: ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced that it has initiated a research collaboration with Dr Shawn Kwatra, as an advisor, from Johns Hopkins University School of Medicine and Dr Madan Kwatra from Duke University Medical Center to investigate the unique role of the IL-13Ra1 subunit, distinct from the role of other pathway components, in Type 2-mediated inflammatory diseases, specifically atopic dermatitis (AD).
The research collaboration will evaluate the role of IL-13Ra1 in moderate-to-severe AD patient samples and will test how IL-13Ra1-mediated allergic, inflammatory and regulatory pathways are affected by eblasakimab¡¦s selective targeting of the Type 2 receptor in contrast to a broader blockade of both the Type 1 and Type 2 receptors seen in current standards of care. The studies will also explore the downstream effects of specifically targeting IL-13Ra1 by eblasakimab and help to further the understanding of the biological relevance of IL-4 and IL-13 signaling. Initial findings from the collaboration will be disclosed for presentation during the second half of 2022.
Shawn Kwatra, MD, is an Associate Professor of Dermatology at the Johns Hopkins University School of Medicine in Baltimore, Maryland, and Director of the Johns Hopkins Itch Center. His areas of clinical expertise include atopic dermatitis, chronic pruritus, prurigo nodularis and dermatology for ethnic skin. Dr Kwatra has been an author or co-author on over 180 publications and is a member of the Board of Directors of the Skin of Color Society.
Madan Kwatra, PhD, is the Director of the Molecular Pharmacology Laboratory in the Department of Anesthesiology at Duke University Medical Center. Dr Kwatra is a receptor pharmacologist and was trained with Nobel Laureate Dr Bob Lefkowitz.
¡§This is an encouraging time in atopic dermatitis with a variety of novel therapies becoming available,¡¨ commented Dr Shawn Kwatra, Associate Professor of Dermatology at the Johns Hopkins University School of Medicine. ¡§To improve treatment options for patients, it is important to focus on obtaining a better understanding of the role of specific disease mechanisms targeted by different groups of therapies, such as the various components of the Type 1 and Type 2 receptor complexes that regulate IL-4 and IL-13 signaling. From advances in psoriasis, where numerous therapies have been developed, we have learned that targeting different subunits in common molecular pathways can have drastically different clinical effects. We are hopeful this study could potentially clarify the distinct roles of the Type 1 and Type 2 receptors and their components in driving AD pathogenesis.¡¨
Dr Ferda Cevikbas, Head Translational Sciences, ASLAN Pharmaceuticals, commented, ¡§This collaboration will help us understand the unique role of IL-13Ra1 signaling in AD, and provide a mechanistic basis for eblasakimab¡¦s differentiation versus other pathway-specific treatments. We are looking forward to working with Dr Shawn Kwatra and Dr Madan Kwatra to generate insights that inform how the differentiated targeting of IL-13-relevant pathways might benefit AD patients who are yet to find relief from this chronic disease.¡¨ |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¬õ¹Ð¦³¹Ú10150039 |
µoªí®É¶¡:2022/6/7 ¤W¤È 08:03:46
²Ä 5369 ½g¦^À³
|
stockhouse.com/news/press-releases/2022/06/06/aslan-pharmaceuticals-to-host-third-webinar-in-a-x2074-kol-series-dialogues-with
¤º®e·N«ä·Pı¬O«üAD¥¼º¡¨¬ªºÂåÀø»Ý¨D¡A¥Ñ004¸É¤W¶Ü¡H ¤j¤jÌ«ç»ò¸ÑŪ |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2022/6/3 ¤U¤È 12:18:41
²Ä 5368 ½g¦^À³
|
Gogoldata ¤½¥q©Ò¥X³ø§i¡A¥X¦b3¤ë31¤é¡A
REGN ¤½¥qDupilumabªº³Ì·s¥Ø¼Ð¾P°â¡A¤w´£¤É±q100»õ欧¤¸¡A´£¤É¨ì130»õ¼Ú¤¸¡C
©Ò¥HDupilumab 2030¦X²z预¦ô 62»õ¬ü¤¸x130/100=80.6»õ¬ü¤¸¡A¸û¦XREGN¤½¥q©Ò¦ô¡C
ASLAN004ªºAD¥«³õ¡A¤W¬Ý40»õ¬ü¤¸¡A¥un2b EASI75¹F 60-69% vs ¹ï·Ó组13%¡C
Atopic Dermatitis Market Size and Trend Report including Epidemiology and Pipeline Analysis, Competitor Assessment, Unmet Needs, Clinical Trial Strategies and Forecast, 2021-2030 Pages: 111 Published: March 31, 2022 Report Code: GDHC243PIDR Add to Saved List OverviewKey PlayersContentsTablesFiguresFAQ The atopic dermatitis market size was valued at $6.4 billion in 2020. The market is expected to grow at a CAGR of more than 10% during the forecast period. Atopic dermatitis (AD) is a chronic or chronically relapsing inflammatory skin disease arising from a complex interrelationship of environmental, immunologic, genetic, and pharmacologic factors. Also known as atopic eczema, it is characterized by pruritus (an unpleasant sensation that elicits the desire to scratch), redness, scaling, and flaking of the skin surface. |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2022/6/3 ¤W¤È 09:42:27
²Ä 5367 ½g¦^À³
|
2030¦~ ¤¤-««×ADÃĪ«¾P°â¹w´ú:168»õ¬ü¤¸/2020¦~64»õ¬ü¤¸¡C
Dupilumab: 60»õ¬ü¤¸¡C Lebrikizumab & Tralo: 22»õ¬ü¤¸¡C JAK2¤fªAÃÄ:35»õ¬ü¤¸(¦³«°Æ§@¥Î)
The atopic dermatitis (AD) market is expected to grow from a value of $6.4 billion in 2020 to $16.8 billion in 2030 in the seven major markets at a compound annual growth rate (CAGR) of 10.1%, according to GlobalData. www.thepharmaletter.com/article/growth-in-atopic-dermatitis-market-to-exceed-10-at-cagr
2022/04/05
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2022/5/19 ¤U¤È 08:34:17²Ä 5314 ½g¦^À³ Eblasakimab may be efficacious against a wide range of AD comorbidities, such as asthma and allergy
Eblasakimab¥i¯à¹ï¼sªxªºAD¦X¨Ö¯g¦³Àø®Ä¡C ¡A¦pý³Ý©M¹L±Ó¯g¡C
p.12 ir.aslanpharma.com/static-files/20941066-3bc3-418b-a970-9951565de0f2
81% of moderate-to-severe AD patients have Type 2 inflammatory comorbidities:
¤¤«¯gAD±wªÌ,±w¦³«¬2ª¢¯gªº¨Öµo¯g81%
¨ä¤¤±w¹L±Ó©Ê»óª¢ªÌ¨Öµo¯g 50% ¨ä¤¤±w¹L±ÓªÌ¨Öµo¯g 38% ¨ä¤¤±wý³Ý¨Öµo¯g 35% ¨ä¤¤±w¹ª«¹L±Ó¨Öµo¯g 34%
Blockade of IL-4 and IL-13 signaling through the Type 2 receptor will be important to address both IL-4 and IL-13 driven comorbidities in AD patients.
Physicians would prefer treatment options that can address these other conditions.
ªýÂ_ IL-4 ©M IL-13 ³q¹L«¬ 2 µo«H¸¹¨üÅé ±N«Ü«n¥i¦P®É¸Ñ¨MAD±wªÌ¦] IL-4 ©M IL-13ÅX°Êªº¦X¨Ö¯g ¡C
Âå¥Í̧ó³ßÅw¥i¦P®ÉªvÀø¨ä¥L¦X¨Ö¯gªºÃÄ¡C
¸ê®Æ¨Ó·½: 237¦ì±wªÌªº¬ã¨s.µoªí©ó2022¦~AAD ¦~·|. Source: Calzavara-Pinton et al (2022) AAD Annual Meeting poster presentation, Baseline patient demographics and comorbidities in patients with atopic dermatitis from the GLOBOSTAD registry (237 patients) -------- |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G³v®ö«È10146323 |
µoªí®É¶¡:2022/6/1 ¤U¤È 07:42:36
²Ä 5366 ½g¦^À³
|
¤H¥Í´N¬OµL¼Æªº¶R¹Ú ¦³¨Ç¦¨¥\¡A¦³¨Ç¥¢±Ñ ³o¨Ç³£¬O¬Û¡A¨ìÀY³£¬OªÅ ¤£¹L¡A¨£¬Û«D¬Û¡A¤S¦ó¶·¦b·N¬Û¡H ¶R ¨Ç°²¬Û¡A¤S¦p¦ó¡H µL·µL«B¤]µL´¸¡ã |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¬õ¹Ð¦³¹Ú10150039 |
µoªí®É¶¡:2022/5/31 ¤U¤È 09:12:22
²Ä 5365 ½g¦^À³
|
¬Û¸û©ó°ê¤º³\¦h·sÃĤ½¥q¡AÁ{§Éªº ³z©ú«×«Ü®t¡AÁ{§É¤½§G«á¦Ñ¤[Á٬ݤ£ ¨ì¶i«× ¦Ñ·àªºÁ{§É³z©ú¦h¤F¡A¦Ó¥B¦³«ùÄòªº¶i®i °£¤FªÑ»ù¤£µ¹¤O¡A¥i¯à©R¹B¦³ÂI§¢©V ´Nºâ¤@´Á¼Æ¾Ú¦³ÂI·å²«¡A¨ì©³ÁÙ¬O¹LÃö¤F ¤£Åo¶Û«ùÄò¶R¶i
¨S«H¤ß´N¥á¥X¨Ó¼Ú¡A¦b¦h¤]¤£¥Î©È¨S¤Hn |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2022/5/28 ¤U¤È 03:20:39
²Ä 5364 ½g¦^À³
|
www.sec.gov/edgar/search/?r=el#/q=Dermira
Dermira/Lebrikizumab ³Q¨ÖÁʳø§i
³Ì°ª¹w¦ôÀ禬2030¦~ ¬ù15»õ¬ü¤¸
**(Lebrikizumab ¹w¦ô2023¦~¤W¥«,²Ä¤@¦~3»õ¬ü¤¸/²Ä¤G¦~5»õ¬ü¤¸/²Ä¤T¦~7.5»õ¬ü¤¸, ¼Ú¬w°Ï¤w±ÂÅv,¶È¦¬ùµ{ª÷¤Î¾P°â¤À¼í))
¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1¶
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2021/3/31 ¤U¤È 04:05:04²Ä 4037 ½g¦^À³ ¬ü°ê¨ÖÁÊ°ª³z©ú«× ÅýªÑªF¦w¤ßÁÈ www.wealth.com.tw/home/articles/21569 2019-07-24 §@ªÌ: ÄǨq¬Ã
½÷·ç114»õ¬ü¤¸¦¬Áʦã·ç¡A¥æ©ö®É¶¡Áöº©ªø(2017¦~1¤ë~2019¦~6¤ë)¡A¦ý¹Lµ{¤½¶}³z©ú¡AÅý§ë¸ê¤H¸ûµLºÃ¼{¡C¡]¹Ï¡þ¨ú¦ÛArray Biopharma©xºô¡^
¥H¥þ²y³Ì¤jÃļt½÷·ç114»õ¬ü¤¸¦¬Áʦã·ç»sÃÄ¡]Array BioPharma¡^¬°¨Ò¡A¥i¥H±q³Q¦¬Áʤ½¥q¦ã·ç»sÃÄ´£¥æµ¹ÃÒºÞ·|ªº¤å¥ó¡A¤@¿sÂù¤è½Í§P¹Lµ{µ¾¹êªº¨ÓÀs¥h¯ß¥H¤Î¤½¥qµû»ùªº¤º²[¡C
2017¦~1¤ë¡A¦ã·ç§ä¨Ó¦b¨ÖÁʮ׫ܦ³¸gÅ窺Centerview Partners¨ÖÁÊ¿Ô¸ßÅU°Ý¤½¥q¡CCenterview´¿¸g¤âªº¥æ©ö°ª¹F3¥ü¬ü¤¸¡A¥B¤½¥q«È¤á¸s¥e¥þ²y«e50¤j¥ø·~ªº20%¡CCenterview«Ü§Ö´N¿z¥X¥|®a¦W³æ¡A¥]¬A½÷·ç¡C
±µµÛ¡A¦ã·ç»sÃĦb2018¦~6¤ë¤À§O¨ú±oBRAFTOVI©MMEKTOVI¦X¨ÖªvÀø¥Ö½§Àù¥H¤ÎGanovoªvÀøC¨x¯f¬rªºÃÄÃÒ¡A11¤ë±ÂÅv¥X¥hµ¹LOXOªºLarotrectinib¤]®³¨ìÃÄÃÒ¡A¤½¥qªº»ùȤ]¤ôº¦²î°ª¡C
2019¦~2¤ë¡A¦ã·ç»sÃĶi¤@¨B§ä¼ç¤O¶R®a¶i¦æ¤@¹ï¤@ªº°Q½×¡A¦P®É¤]¸Õ±´½÷·çªº·NÄ@¡C3¤ë¤¤¡A¦ã·ç»sÃÄ©M½÷·ç¨M©w¥ýñ«O±K¨ó©w¡A±µµÛ½÷·ç°ª¼h¿ËÁ{¦ã·ç¡A»PÀç¹BªøAndrew Robbins©M·~°ÈÀYÀYNicholas Saccomano¶i¦æ§ó²`¤J°Q½×¡C5¤ë17¤é¡A¦ã·çÀç¹Bªø³z¹L¹q¸Ü»P½÷·ç°ÆÁ`John DeYoung»P¬ãµoªøChristopher Boshoff¤À¨ÉªvÀø¸zÀùªºBEACONÁ{§É¥O¤H¿³¾Äªº¼Æ¾Ú¡]Âù¤è¦³Ã±«O±K¨ó©w¡^¡C¤£¹L½÷·çÁÙ¬O¨S¦³´£¥X¦¬ÁÊ»ù®æ¡A·í®É¦ã·çªÑ»ù¤w¸gº¦¨ì¤j¬ù21¬ü¤¸¡C
5¤ë21¤é¦ã·ç»sÃÄ¥¿¦¡¦V¥«³õ¤½¥¬BEACON¤T´Á¼Æ¾Ú¡A¤TÁpÃĦbªvÀø¤W¬Û¸û¤ÆÀøÃĪº¤ÏÀ³²v¡]26.1%¡B1.9%¡^©M¾ãÅé¦s¬¡´Á¡]9Ó¤ë¡B5.4Ó¤ë¡^¡A¦¹¥~¥i¥H´î¤Ö¦º¤`48%¡A¦P®É«Å¥¬¤U¥b¦~¥Ó½ÐÃÄÃÒ¡C³o¤TÁpÃĪº»ùȦb©ó¡A¦pªGÀòã±N¬O²Ä¤@Ó°w¹ï¸ÓÀù¯gªº«D¤ÆÀøÀøªk¡C§Q¦h¤½¥¬¤]±a°ÊªÑ»ù¤jº¦18%¡A¨ì25.77¬ü¤¸¡C
3¤jª¾¦WÃļt·m¿Ë ½÷·ç²v¥ý·mñ«O±K¨ó©w
¥Ñ©ó¦ã·ç»sÃĤ]¥¿»P¨ä¥L¨â®aÃļt°Q½×¦¬Áʪº¨Æ©y¡A¦P®ÉÀHµÛªÑ»ù¤@¸ô¤Wº¦¡A½÷·ç¤]¤ß«æ¤F¡C5¤ë29¤é¡A½÷·ç³Ì°ª¥DºÞ°õ¦æªøAlbert BourlaÁpµ¸¤F¦ã·ç»sÃÄ°õ¦æªøRon Squarer¡A§iª¾¥H¨CªÑ44¬ü¤¸¦¬Áʦã·ç»sÃÄ¥þ³¡ªÑ¥÷¡C
¤£¹L¡A¦ã·ç»sÃħƱ洣°ª»ù®æ¡A½÷·ç¤]©È¦³30ÓÁ{§É¶i¦æ¤¤ªº¦ã·ç»sÃĤS¦³·sªº¼Æ¾Ú¤½¥¬¡A´X¤Ñ«á°¨¤W¦^À³´£°ª¬°48¡A·¸»ù¦¬ÁÊ¡C2019¦~6¤ë14¤éÂù¤è©ó¦¬½L«áñ¤U¨ÖÁʨóij¡A¨Ã©ó6¤ë17¤é¦±á¤½¥¬¨ÖÁÊ°T®§¡C
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2022/5/28 ¤U¤È 03:10:08
²Ä 5363 ½g¦^À³
|
1.2017/08/08 (2019/10 ¤T´ÁÁ{§É¶}©l) Dermira¦Vù¤óROCHE ,ÁʶR Lebrikizumab¥þ²yAD¶}µoÅv«eª÷8000¸U¬ü¤¸¡A2018¦~¦A¤ä¥I5500¸U¬ü¤¸¡C ±Ò°Ê²Ä¤@Ó3´Á¤§«e¤ä¥I4000¸U¬ü¤¸¡A¦b¬Y¨Ç¦a°Ï¨ú±oÃÄÃÒ©Mº¦¸°Ó·~¾P°â¨ã¦³¨½µ{¸O·N¸q®É¤ä¥I2.1»õ¬ü¤¸¡A°£¶¡½è©ÊªÍ¯f¥H¥~ªº¾AÀ³¯gªº²b¾P°âÃB¹F¬Y¨Ç»ùȳ̰ª¹F¨ì10.25»õ¬ü¤¸,¦Xp¬ù14»õ¬ü¤¸,¥[¾P°â¤À¼í<= 10%. Áô§t28»õ¬ü¤¸³Ì°ª¾P°âÃB.
Âê©wIL13 °tÅ餧¼Ð¹v ¥ØªºªýÂ_IL-13R£\1»P IL-4R£\1¤§°T®§¶Ç»¼¤§¾÷Âà
2.2018¦~2¤ë ¡ADERM¬YÓ·sÃĤT´ÁÁ{§É¸Ñª¼¥¢±Ñ¡AªÑ»ù±q30¬ü¤¸/ªÑ¡A¤j¶^¦Ü8¬ü¤¸/ªÑ¡C
2.1 , 2019/02,Lebrekizumab ¡AAD 2b¸Ñª¼¦¨¥\¡C 2019/02 ,Dermira ¦A±Â¥X¼Ú¬wLebrikizumab °Ó·~¤ÆÅv¤Oµ¹Almirall,¤½¥q.
Out-License and Other Agreements Almirall Agreement
¤W¤@Ó¤T´Á¸Ñª¼¥¢±Ñ¡AªºDERM¤½¥q ¥t¤@Ó¤À¤lLebrekizumab 2b AD¸Ñª¼¦¨¥\¡A ¨Ã¦b°µ¤T´ÁAD¡A¶}©l5Ó¤ë内³Q¨ÖÁÊ¡C
ROCHE ¤w°µ§¹Lebrikizumab ý³Ý/OECD ¤T´ÁÁ{§É¥¢±Ñ¡A«á¤~¦b2017¦~8¤ë±ÂÅv给DERM¤½¥q¡C |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2022/5/28 ¤U¤È 02:49:00
²Ä 5362 ½g¦^À³
|
www.netcials.com/stock-price-chart-history-nasdaq/DERM-Dermira-Inc/
¬Ý¬ÝDerm ¤½¥q¡A¾ú¥vªÑ»ù 2020¦~2¤ë³Q§¨Ó11.1»õ¬ü¤¸¨ÖÁÊ¡C 2018¦~¡A§ÞÂàLebrikizumab¦ÛROCHE, ¶}©l°µAD 2b.
2019¦~ªì2b AD¸Ñª¼¦¨¥\¡A¼Ú¬w±ÂÅv¡A¼W资4»õ¬ü¤¸¡A°µ3´Á¡C 2019¦~10¤ë ¶}©l°µAD¤T´Á¡C
18.75¬ü¤¸/ªÑ¡A³Q¨ÖÁÊ(¥«È11.1»õ¬ü¤¸)
¬üªÑº¦¶^´TµL¤W¡C
¦U¶¥Á{§É¯à¤ÏÀ³
ªÑ»ù¨«¶Õ? ¯à¤ÏÀ³©M³Q¨ÖÁÊ»ùÈ¡H¡H¡H
¤£¯à¡I¤£¯à¤ÏÀ³¡C
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G«Ó°¶10144972 |
µoªí®É¶¡:2022/5/28 ¤U¤È 01:26:25
²Ä 5361 ½g¦^À³
|
¦Ñ·à¤Í³£¸g¾ú¹L001³sÄò¥¢±Ñ ¤°»òGÀù¡BÁx¹DÀùµ¥µ¥ªº... ¦ý·sÃĤ£´N¬O³o¼Ë¤@½¨âÀü²´¡A¼Æ¾Ú¦nµ²ªG¤]¤£¤@©wºÉ¦p¤H·N «Ü¦h·sÃĤ½¥q¤]³£¬O¤@¶}©l¥¢±Ñ¡A³Ì«á¦]¬YÓÃĽÂà ¨Ò¦p¹j¾À§Y±N¤W¥«ªº¥_·¥¬P¡A¤]¬O¦h¦¸¥¢±Ñ¶^¨ì¹³nˤF¡A¦p¤µ¬Ý¨ì§Æ±æ §Ú·Q§ë¸ê·sÃÄ´N¬O³o¼Ë§a ¹ïªÑ»ù¨«¶Õ¬Ý¹ïªº¤Hºâ§A¼F®`¡A¦ý¤]¤£»Ýn¨Ó¬Ý°I¤j®a ¤@®Éªº¥¢±Ñ¤£¤@©w³Ì«á¥¢±Ñ ¦¨¥\´N¦¨¥\¡A©È¥¢±Ñ´N°h³õ¡A¤Ï¥¿§ë¸ê¤]¤£¬O¥u¦³³o¤@¦¸ ¥un§A¤£¬OÀ£¨®a°µ¦h¦P¤@ÀÉ ³o³£¥u¬O§ë¸êªº¤@Ó¹Lµ{ |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¬õ¹Ð¦³¹Ú10150039 |
µoªí®É¶¡:2022/5/28 ¤U¤È 12:34:40
²Ä 5360 ½g¦^À³
|
¤Ï«ü¼Ð°T¸¹¶V¨Ó¶V©úÅã¤F¡A§Ú¬Ý³Ñ¤U ªº¸êª÷¡A¬O®ÉÔ¶i³õ¤F |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡GDHL10147526 |
µoªí®É¶¡:2022/5/28 ¤U¤È 12:18:23
²Ä 5359 ½g¦^À³
|
ASN001§Ú¤]¸g¾ú¹L¡I ³oª©·U¨Ó·U¦h¼Ë¡Aºë±mºë±m¡I ¤@¦~«á´N¤@½¨âÀü²´ ¤U¦nÂ÷¤â ¤£¬Ý¦n´N¥ý¶]§a¡I
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡GªL³Ò¬I10152784 |
µoªí®É¶¡:2022/5/28 ¤W¤È 11:26:30
²Ä 5358 ½g¦^À³
|
ÁÙ¬O©ú¤Ñ¹L«á¤j²M¿ô ªÑ»ù¤~·|»¡¹ê¸Ü ¨º¨Ç§ë¸ê³ø§i»P¼Æ¾Ú ³£«Ü¦³°ÝÃD
·íªì ASLAN 001ªº³ø§i,¼Æ¾Ú, ¼v¤ù ¦³¦h¦n ÁÙ¤£¬O±¾±¼?
¤j®a·í§@²î¹L¤ôµL²ª ÁÙn¤W²Ä¤G¦¸·í??
»{¬°ASLAN 004ªº³ø§i,¼Æ¾Ú, ¼v¤ù ¦³¦h¦n
½Ð¥ý¦^µª ASLAN 001 ¤£¤]¨«¹L¤@¼Ëªº¸ô? ¼Æ¾Ú¦³¦h¦n Åܦ¨¼Æ¾Ú·¥®t ºtÅܦ¨²×¤î¶}µo
ªÑ»ù¤~¬O³Ì¸Û¹êªº Y¯u¦³¼ç¤O ªÑ»ù¤£·|¤@ª½©¹¤U¨«¨ì¹sÂI´X ¥«³õ¤@©wª¾¹D
¼Æ¾Ú¦n¬Ý, ªÑ»ù¤@ª½©¹¤U¨« ¨«¨ì§Ö¤U¥« ¨º´N¬O¦³¼Æ¾Ú¦³°ÝÃD,©Î¦³¥¼´¦ÅS¤j§QªÅ¤º¹õ!
¥«³õÁͶլO³Ì·Ç½Tªº µ´¹ï¤ñ¥»ª©ªºº¡ª©ÁٷǽT
§Æ±æ¤£n¨ì³Ì«á¤S¥¢±Ñ¤F ¦A´£¤@¦¸¤»¯ªÁI®vªº¸Ü ²î¹L¤ôµL²ª |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡GªL³Ò¬I10152784 |
µoªí®É¶¡:2022/5/28 ¤W¤È 11:12:20
²Ä 5357 ½g¦^À³
|
³oÃ䪺¤H»¡§Ú¦b±À¦X¤@ §Ú³£»¡§Ú¤£¬Ý¦n¦X¤@¤F
«ç·|¸£¸É¬Ý¦n??
¦X¤@¬O¤¤Q¨B ¨È·à±d¬O¦Ê¨B¤d¨B ³o·§©ÀÁÙ¤£À´??
¤j®aÁÙ¦b¯º¤¤Q¨B?? ³o¬O¦Ê¨B¯º¤¤Q¨Bªº·§©À?? |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G³¯¤p©ú10152293 |
µoªí®É¶¡:2022/5/28 ¤W¤È 06:51:42
²Ä 5356 ½g¦^À³
|
§Ú¤£»{¬°¥L·|¦³¥ß§Y¤j¿¼Æ¤Ï¼uªº±¡§Î
²¦³º¦³¤Ó¦h¼h¼h®M¨cªºÄw½X ¥u§Æ±æ¤£¦A¯}©³¡A¦b¦¹¿vÓªø©³ §Q¥Î¥¼¨Ó¦³¯u¥¿§Q¦h®ø®§ «·s¯¸¤W¬üª÷1¤¸¦ì¸m ¤Æ¸Ñ¤U¥«ªº¦M¾÷§Y¥i
¨ä¥L¤@¤Áµ¥©ú¦~2b¸Ñª¼µ²ªG
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¥xÁÞ10138776 |
µoªí®É¶¡:2022/5/27 ¤U¤È 11:32:39
²Ä 5355 ½g¦^À³
|
·íªì2~6¤¸½æ±¼ªº¤H²{¦b¥i¥H5~15¿ªºªÑ¼Æ¶R¦^¡A£¸¦³§Q¦hÁ`¶R¶iªº¤O¹DÃø¥H·Q¹³¡A¤£n§Ñ¤F ¨S¦³º¦¶^´T¨î¡A¤£n³QÀ~¨ì¦Ó½æ¥X¡AÂê°_¨Ó¤ñ¸û«OÀI¡A§ë¸ê´N¬O½ä¦¨¥\¾÷²v¡A¥Ö½§¯f¦b¤G´ÁÁ{§É¦¨¥\¾÷²v¬ù¦Ê¤À¤§55¥ª¥k¡A¦³¼Ð¹v·|°ª¤@¨Ç¡A¦¨¥\ªº©w¸q¤£¬O£¸©wn¤ñ§OªºÃĦn¡A¦Ó¬O¥i¥Hº¡¨¬¤£¦P±Ú¸sªº»Ý¨D¡C |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G³¯¤p©ú10152293 |
µoªí®É¶¡:2022/5/27 ¤U¤È 09:53:56
²Ä 5354 ½g¦^À³
|
²{¦b¤ß±¡¬O ¦º½Þ¤£©Èºu¤ô¿S ¦º°¨·í¬¡°¨Âå
ÁÅ¥X¥h¤F¡A ·í§@¶R¤¤¼ú²v·¥§Cªº«Â¤O±m
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G«Ó°¶10144972 |
µoªí®É¶¡:2022/5/27 ¤U¤È 08:45:28
²Ä 5353 ½g¦^À³
|
²{¦b0.4¤¸©Î0.1¤¸©Î0.8¤¸¦³®t¶Ü? ¤Ï¥¿³£¬O¬Ý004³Ì«áµ²ªG ¤£¬OÃz±¼´N¬O¤jÁȤ@µ§¨«¤H ³o´N¬O½ä³Õ¼Ö³z¬Ý¨Ó©ú¤Ñ¤jÁÙ¬O¤£À´ ±z¬O¨ÓÄU¥@¶Ü?¦b½ä®{±«e¤ñ¸û¹³¸¨¤«¤U¥Û¤@ÂI |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G©ú¤Ñ¹L«á10151242 |
µoªí®É¶¡:2022/5/27 ¤U¤È 03:08:40
²Ä 5352 ½g¦^À³
|
¥Ø«e¤w¸g¤U±´0.4¤§¤U¤F,´«ºâ¦¨¥xªÑ»ù®æ¤j¬ù2.4¶ô¥ª¥k,ªñ´Á¤º¨S¦³«¤j§Q¦h®ø®§ªº¸Ü,ªÑ»ù´N·|¬O¦b©¹¤U¾_Àú,¤£¹L©¹¤U¦h¤Ö¤w¸g¤£«n¤F!
·|û¡G©ú¤Ñ¹L«á10151242 µoªí®É¶¡:2022/3/2 ¤U¤È 11:16:14²Ä 5145 ½g¦^À³ ¤§«e¥»¤Hªº¯d¨¥³£¤w¸g¤@¤@ÅçÃÒ.......ªÑ»ù¤w¸g©¹0.8¾aªñ ! ±µ¤U¨Ó·|ºCºC¤U±´¨ì0.4¥ª¥k ! ³ÌºGªº¬O¦pªG30¤Ñ¤ºªÑ»ù³£¯¸¤£¤W1¶ô¿ú~ÁÙn±Á{¤U¥«·ÀI ~ ¤£¹L¬üªÑ«Ü¬y¦æ¤À©îªÑ²¼´î¤Ö§AªºªÑ¥÷µM«á¼W¥[ªÑ²¼±È¨ÓÁקKªÑ²¼¤U¥«...§Æ±æ¨È·à±d¤£n¨«¨ì³o¤@¨B
·|û¡G©ú¤Ñ¹L«á10151242 µoªí®É¶¡:2022/1/19 ¤W¤È 09:59:39²Ä 5061 ½g¦^À³ ¶ZÂ÷¤W¦¸¯d¨¥(2021/12/28)¹L¤F¤j¬ù20¤Ñ~¨ì¤F¤µ¤Ñ¥Ø«e¤w¸g¶^¸¨1¶ô¤§¤U... (2021/9/29)¸Ñª¼¤j¶^¤§®ÉÁÙ¦³2.5¶ô,¥B·í®É¥»¤H¤w¸gÂ_¨¥¤§«áÁÙ·|«ùÄò¤j¶^... ¬Ýªk¨Ì¤£ÅܱNÄ~Äò©¹0.8¾aªñ~¦A¨Ó´N¬O©¹0.5»ù¦ì¾aÃl.... ¤d¸U¤£n¬Û«H±Ë»ò³o·sÃĤñ±Ë»òÁÙn¦nªº°¸Ü ? §Aª¾¹D¥«±¤W¾AÀ³©Ê¥Ö½§ª¢·sÃĦ³¦h¤Ö¶Ü ? ª¾¹D¤F§A´N¤£·|Ä~Äò§ë¸êASLN¤F....
³¯¤j§Aªºµo¨¥¨S¦³°ÝÃD~¤£»Ýn³Q¤H«Â¯Ù~~¤]¤£·|¦³ªk«ß³d¥ô !
·|û¡G©ú¤Ñ¹L«á10151242 µoªí®É¶¡:2021/12/28 ¤U¤È 01:43:58²Ä 5008 ½g¦^À³ ¥H¤U¬O2021/9/29¸Ñª¼¨ì¤µ¤Ñªº¬Ýªk.... ¥»¤H1´Á¸Ñª¼¤j¶^·í¤Ñ¬å¥X»ù¦ì2¶ô5¥ª¥k!!¨ì¤µ¤Ñ¤S¶^¨ì1¶ô¿ú¤W¤U~²{¦bªºªÑ»ù¤w¸gÅçÃÒ·í®Éªº¬Ýªk~ ¤§«áÁÙ·|©¹0.8¾aªñ~¤£«H¶Ü ? ½Ð±µµÛ¬Ý !! ºô¸ô°g´öªGµMÁÙ¬O·|¨R©ü¤@°ï¤H°Ú~½Ð¦Û¤v¤p¤ß!!
·|û¡G©ú¤Ñ¹L«á10151242 µoªí®É¶¡:2021/10/23 ¤U¤È 05:55:34²Ä 4784 ½g¦^À³ ¬Q¤é«ùÄò¤j¶^7%¤¤~«Ü¼y©¯¥»¤H¦b¨È·à±d¬ü¤Æªº1´Á¸Ñª¼¼Æ¾Ú..¦ý¥«³õ¤£»{¦P¤j¶^«á...¦b2¶ô¦h´N¥þ¼Æ¥X²æ.. ¤§«e¤w¸g»¡¹LªGµM¤j¶^«áÁÙ·|«ùÄò³Ð·s§C...¥¼¨Ó±NºCºC½w¶^¨ì¤@¶ô¤§¤U..¤d¸U¤£n¤£¬Û«H ?
·|û¡G©ú¤Ñ¹L«á10151242 µoªí®É¶¡:2021/10/15 ¤U¤È 07:49:46²Ä 4750 ½g¦^À³ ¥H¤U§ó¥¿¬°004 ¤j®aÁÙ°O±o¶Ü¡H ¨È·à±d³£¬O¤@³eªº§@·¡A¤§«eÁx¹DÀù¤T´Á¥¼¸Ñª¼¤§«e¤]¬O³£«Ü¼ÖÆ[¡AµM«á³oÃ䪺ºô¤Í±M·~¤ÀªR¤å³¹³sµo¡I»¡¦³¦h¼F®`¤@©w·|¹L¤T´Á¡Aµ²ªG¤@¸Ñª¼¥¢±ÑªÑ»ù¤j¶^¡A³oÃ䪺ªº°l±·¤å³¹ÃÒ¾Ú¤]³£¤@°_¬å±¼¤F¡AµM«á²{¦b¦A¨ÓÓ004¡K ¬Ý¦ü«Ü±M·~¼Æ¾Ú¤å³¹Ä~Äò°l±·¡A¦ý¨Æ¹ê004´N¬O¼Æ¾Ú¤£¦n¡AÃø¤£¦¨¨gµo¬Ý¦ü±M·~ªº¤å³¹¡A¨È·à±d´N·|ùL¤G´Á¶Ü¡HµM«á³Q¦¬ÁÊ¡H ·í§½ªÌ°g¡A®ÇÆ[ªÌ²M¡A½Ð¤T«ä¡K
·|û¡G©ú¤Ñ¹L«á10151242 µoªí®É¶¡:2021/10/12 ¤U¤È 03:24:19²Ä 4709 ½g¦^À³ Ó¤Hı±o³o¦¸¤£¬OÀ£§C¥X³f¸ÑŪ, ¦U¦ì¦³¬Ý¹L¼Æ¾ÚÀu¦ý¬OªÑ»ù¶^±¼¤@¥bªºªº¨Ò¤l¶Ü? ³q±`¼Æ¾ÚÀu³£¬Oº¦¤@¿!¤£·|À£§CÅý§A¦Y³fªº©Ô! ¨S·N¥~ªÑ»ù·|½w¶^¨ì1¶ô¤§¤U~
¥H¤U¬O9¤ë©³ªº¬Ýªk¦Ü¤µ¤£ÅÜ...½w¶^¨ì§A¤ß·W·N¶Ã...
·|û¡G©ú¤Ñ¹L«á10151242 µoªí®É¶¡:2021/10/6 ¤U¤È 02:49:51²Ä 4668 ½g¦^À³ ¥«³õ¤W°µÃþ¦üªºÃįuªº¤Ó¦h¤F~³Ìªñ1¦~¨Ó¦³´X®a¬Û¦PÃĪ«1´Á¸Ñª¼«á³£¤jº¦5¦¨~1¿¥H¤W,¦ý¥u¦³¨È·à±d¦V¤U¶^±¼¤@¥bªÑ»ù¥H¤W, ¦pªG¯uªº¦p³oÓªO¤W¤ÀªRªº¼Æ¾Ú¨º»ò¦n,ªÑ»ù¬°¦óÁÙ¬O«®À??Ãø¹D¬O¨º¨Ç§ë¸ê¾÷ºc¥þ³¡¬Ý¨«²´½M¤F¤£±¤¦¨¥»¤@¸ô¨g½æ? ¨Æ¹ê¬O¨È·à±dªº¼Æ¾Ú´N¬O®t©ó¹w´Á,¤§«á¤]¤£·|¦³±Ë»ò¤H·|¨Ó½Í±ÂÅv©Î¬O¨ÖÁÊ,ªÑ»ù±N·|½L¶^¨ì1¶ô¿ú¥H¤U....
·|û¡G©ú¤Ñ¹L«á10151242 µoªí®É¶¡:2021/10/6 ¤W¤È 08:53:03²Ä 4663 ½g¦^À³ ¥H¤U¬O 9/29 ªº¬Ýªk ¦Ü¤µ¤£ÅÜ
·|û¡G©ú¤Ñ¹L«á10151242 µoªí®É¶¡:2021/9/29 ¤W¤È 09:06:30²Ä 4559 ½g¦^À³ ¬Û«H¶R¨È·à±dªº¦U¦ì¤j¤j,¥¼¶}¼ú¤§«e³£¦bÀqÀq½Lºâ,§Úªº¦Ê¸U§ë¸ê¦b¤E¤ë¸Ñª¼«á·|½¦¨¦n´X¿·Ç³Æ¶R¨®¶R©Ð¤F,¦ý³o¦¸¶}¼úµ²ªG´N¬O¤£¦p¹w´Á,§Ú¥i¥H§i¶D¦U¦ì°ê¥~¦U§ë¸ê¶R®a¹Î¶¤¬O¤£¶R³æªº,¤]¤£n¬Û«H±Ë»ò§ë¸ê¾÷ºcµ¹¥Ø¼Ð»ù8¶ô¿ú(³o¨Ç³£¬O½æªÅªº¦nªB¤Í,§Aªº¿ú³£¬O³Q³o¨Ç½æªÅªÌÁȨ«)! °ê¥~ªº§ë¸ê¹Î¶¤¤£¬Oªxªx¤§½ú,I«á¬ã¨s¹Î¶¤ªº¥\¤O¤£ª¾¹D±j¹L³oÓª©ªº¬Y¨Ç¤ÀªR¼Æ¦Ê¿!¤]¤£·|¸ò§AºtÀ¸..¦n¼Æ¾Ú´N¬O¤j¶R,Äê¼Æ¾Ú´N¬O¤j½æ! ¦pªG¯uªº¹Ú¿ô¤F´NÅý¥L¿ô§a,¤d¸U¤£n¨I¾K¦b¹Ú¸Ìn¶}©l¾Ç·|±¹ï²{¹ê ! ¬üªÑºD©Ê¦pªG¤j¶^«áªº¹j¤ÑÁÙ¬O¤j¶^,¤§«áªº¼Æ©P±N·|«ù³Ð·s§C,¤£«H¶Ü ?11¤ë1¤é¤j®a¨ÓÅçÃÒ ! |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2022/5/27 ¤W¤È 08:51:22
²Ä 5351 ½g¦^À³
|
EASI75(¦©°£¹ï·Ó²Õ)Àø®Ä PK
¤@.¨ÌITT¤ÀªR, EASI75(¦©°£¹ï·Ó²Õ)Àø®Ä ASLAN004 37% (P<0.05) VS Dupilumab32%~36% (P<0.05) VS FB825 ¦ô10%¥ª¥k(24.4%*1/3+2/3(«D¥Ø¼Ð±wªÌ)*0%=8.1%, ©M¹ï·Ó²ÕµL²Îp¤Wªº©úÅã®t²§,p>0.05, )
¤G.¨ÌRITT¤ÀªR<ç°£§CTRAC²Õ>
EASI75(¦©°£¹ï·Ó²Õ)Àø®Ä
ASLAN004¡A¤j´T»â¥ý¨ä¥L¨âÃÄÁͶաI
EASI75(¦©°£¹ï·Ó²Õ)Àø®Ä ASLAN004 54% VS Dupilumab28%~32% VS FB825 24.4%
---------------------------------------------------------------- <ç°£§CTRAC²Õ¤ÀªR>°ò¥»¸ê®Æ ---ASLAN004 ©Òç°£¬°°ò½u§CTRAC <1115,§CIgE<1/10¥L²Õ¼Æ,§CEASI<20,¤T§C²Õ, ¹êÅç²Õ6¤H,6/22=27%
---Dupilumab °ò½u§CTRAC <1115 ¦û¬ù30% ¨ä¥§¡EASI=25,§CIgE ¦û¬ù15% ¨ä¥§¡EASI=25 ¦ôp°ò½u¦PASLAN004 §CEASI<21,¥B§CIgE²Õ¥X²{¤ñ¨Ò0%~3.75%, (15%/2/2=3.75%)
---FB825 ç°£¡A¥»¸ÕÅç2/3¨ü¸ÕªÌTARC°ò½uȧC©ó700 pg/ml (Äv«~ÃĪ«Dupixent¦¬®×°ò½uȬ°1,953-6,147 pg/ml)¡B IgE°ò½u¥§¡È569 IU/ml (Dupixent¬°2,451-10,754 IU/ml)
--ASLAN004 1b ç°£6/22=27% ¡A --Dupilumab PH3*2Á{§É,ç°£300/900=30% ¡A --FB825 2Aç°£66/99=67% ¡A
----------------------------------------------- Lebrikizumab 2bÁ{§É,°ò½u¶}©l«eªº¤H¿ï¿z¿ï¥h°£²v51%
www.ncbi.nlm.nih.gov/pmc/articles/PMC7142380/
424 ¤H°Ñ¥[¿z¿ï ,280¤H¶i¤J¤G´ÁÅç§ÉªºÀH¾÷¤À°t, ¥h°£²v : (424-280)/280=51%
¯uªºÄY®æ¿z¿ï.
---------------------------------------- ·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2022/5/15 ¤U¤È 07:17:40²Ä 5310 ½g¦^À³ Dupilumab 2Ó¤T´ÁÁ{§É,°ò½u¶}©l«e35¤Ñ¶¡ªº¤H¿ï¿z¿ï¥h°£²v36.3%
1.SOLO1 ,Out of 917 participants, 671 were randomized (¿z¿ï¥h°£±¼917-671=246¤H, ¥h°£²v36.6%) 2.SOLO2, Out of 962 participants, 708 were randomized (¿z¿ï¥h°£±¼962-708=254¤H, ¥h°£²v35.8%) ¤pp 1879 ¤H°Ñ¥[¿z¿ï ,1379¤H¶i¤J¤T´ÁÅç§ÉªºÀH¾÷¤À°t, ¥h°£²v: (1879-1379)/1379=36.3%
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G§d½n¶¯10142119 |
µoªí®É¶¡:2022/5/27 ¤W¤È 08:50:49
²Ä 5350 ½g¦^À³
|
¤½¥q°ª¼h¹ïADÁ{§É¦³Â×´I¸gÅç¡A¥i¥H¬d¤@¤U¥L̪ºI´º ¥[¤WIQVIA¾Þ½L¡A§ä¹ï¯f¤H¡AÁ{§É¼Æ¾Ú´N¤£·|°¾®t¤Ó¦h ð¦ÑÀn¡A§A¦Y¹¡¨S¡H
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G©t¨àÃÄ10140658 |
µoªí®É¶¡:2022/5/27 ¤W¤È 08:08:08
²Ä 5349 ½g¦^À³
|
¦Ñ·àªºÃöÁ䦨±ÑªºÃöÁä¦b©ó¡A¦p¥ý«e¤Ñ©R¤j©Ò´£ªº¯f±wªº¿z¿ï¡AÁÙ¦³¥t¤@Ó·¥§C¾÷²vµ²½¤ª¢¬O§_¯à¹ê²{¡AY¯àº¡¨¬«ez±ø¥ó¡A¨äÁ{§É«ü¼Ð¤ñ§ù¥²ª¢¦nªº¾÷²v¬O«Ü°ªªº¡A§Æ±æ©_ÂÝ»PÃĪº¥»½è¯àµo¥Í¤Îµo´§¡Cªü·à¥[ªo!!! |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2022/5/26 ¤U¤È 09:32:31
²Ä 5348 ½g¦^À³
|
ir.aslanpharma.com/static-files/bb612c0d-d08f-4f7a-a433-336d603968bc P.117 ¤½¥q¦~³ø
CEO Carl Firth, Ph.D ªºªÑ²¼¿ï¾ÜÅv²Öp2,382,296 ªÑADR + ì¥ý¬ù600,000ªÑADR=¬ù2,982¤dªÑ, ¦ûASLN ¬ù4.3%«ùªÑªº¤jªÑªF. |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G³¯¤p©ú10152293 |
µoªí®É¶¡:2022/5/26 ¤U¤È 09:15:05
²Ä 5347 ½g¦^À³
|
ªL³Ò¬I¤j ¦X¤@¬ãµoÃĪ«¦³ON101³t¥²¤@¡BFB825¡BFB704A SNS812¡BOB318¡BFB918µ¥ÃĪ« ¨ä¤¤ON101³t¥²¤@¬O¿}§¿¯f¨¬Âå¥Í³B¤è¥ÎÃÄ¡A¤£¬OAD¯SÀ³©Ê¥Ö½§ª¢¥ÎÃÄ ON101¤w¨ú±o¥xÆWÃÄÃÒ¡A¥Ø«eª½¥¿¦b¥Ó½Ð¤¤°êÃÄÃҤάü°êÂå§÷¤¤ FB825¤~¬O¬ãµo¯SÀ³©Ê¥Ö½§ª¢¥ÎÃÄ |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡GDHL10147526 |
µoªí®É¶¡:2022/5/26 ¤U¤È 09:09:41
²Ä 5346 ½g¦^À³
|
Y§A¬O³Å«i¡A²{¦b«ç»ò¿ì¡H ¨S¾÷·|¡G¶]¤£¶]¸ô¡AÁÙ¬OÄ~Äò»âÁ~¤ô¡A»â¨ì¤½¥q˳¬. ¾÷·|¤@¥b¤@¥b¡G¬O¤£¬OÄ~Äò½ä½ä¬Ý¡H ¦³³Óºâ¡GÄ~Äò«÷¤U¥h¡I
§Ú¬Û«HÀ³¸Ó¬O¾÷·|¤@¥b¤@¥b©ÎªÌ¦³³Óºâ. ¤£µM¦´N°{¤H¤F¡C
·|¤£·|¦¨¥\¡A»Ýn§ä¤èªk.
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G³¯¤p©ú10152293 |
µoªí®É¶¡:2022/5/26 ¤U¤È 09:00:05
²Ä 5345 ½g¦^À³
|
²{¦b»¡¤°»ò¦n¤£¦n¡A§Ú³£¤£·|¦b·N¤F ¦Ñ·à±q¥xÆW¸ò¨ì¬üªÑ Áö¿é¤F¤@§¾ªÑ¡A¦ý¤]¬O¦Û¤vªº¿ï¾Ü ¥un¤£¼vÅT®a®x¥Í¬¡ ¦b³oªÑ»ù§CÂI¡A½æ¤F¤]µLÀÙ©ó¨Æ
§Ú¤w¸g±q¦¨¥»¨CªÑ¬üª÷3.8¤¸¡A Åu¥¨ì¥»ª÷¨CªÑ¤£¨ì¬üª÷1¤¸ ©ñµÛ´N·í¶R¤j¼Ö³z
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G«Ó°¶10144972 |
µoªí®É¶¡:2022/5/26 ¤U¤È 08:27:49
²Ä 5344 ½g¦^À³
|
©~µM¦³¤H¨Ó·àª©±Ð¤j®a½ä¦X¤@ ¹ê¦b¬O¤Ó¦n¯º¤F §Ú¤]¤£»{¬°·à¤l¤@©w¦¨¥\ ¦ý¦X¤@...ÁÙ¬Oºâ¤F§a ¤£Ä±±o¤ñ²{¦b¶W§C»ùªº·à¤l¦n
§Ú´N»¡ª©¤Í̸ò³o»ò¤[¤F ¤@©w¬O¸ò¨ì³Ì«á¡An¹À¦¨¥\n¹ÀÃz±¼ ¦A´«¥h¦X¤@Ãz¤@¦¸? ·à¤l©ñµÛ¡A¤£¥[½XÅu¥µL±ýµL¨D §ë¸ê¥«³õÁÙ¦³«Ü¦h¦nªF¦è¡A³o¦¸¥¢±Ñ¦A±q§O³BÁȦ^¨Ó§Y¥i |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2022/5/26 ¤U¤È 07:51:04
²Ä 5343 ½g¦^À³
|
×¥¿: Y¨ÌITT¤ÀªR, EASI75(¦©°£¹ï·Ó²Õ)Àø®Ä ASLAN004 37% (P<0.05) VS Dupilumab32%~36% (P<0.05) VS FB825 ¦ô10%¥ª¥k(24.4%*1/3+2/3(«D¥Ø¼Ð±wªÌ)*0%=8.1%, ©M¹ï·Ó²ÕµL²Îp¤Wªº©úÅã®t²§,p>0.05, ) |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2022/5/26 ¤U¤È 07:43:54
²Ä 5342 ½g¦^À³
|
FB825 2A a.¥Dnµû¦ô«ü¼Ð¤§²Îpµ²ªG¤Î²Îp¤W¤§·N¸q: (a)®Ú¾Ú°õ¦æ¥»¸ÕÅ礧°ê»ÚCRO¤½¥q´£¨Ñ¸ÕÅç¸Ñª¼§¹¾ã¼Æ¾Ú¡A¦b¥»¸ÕÅçµ²§ô«á©Ò °õ¦æ¤§©Ò¦³¨ü¸ÕªÌ¦å²G¥Í¤ÆȤÀªR¡AÅã¥Ü¦³2/3ªº¨ü¸ÕªÌ¤£²Å¦X¥Ø¼Ð±Ú¸s- ¤¤««×²§¦ì©Ê¥Ö½§ª¢(AD)¤§¥Í¤Æ«ü¼Ð¡A¦b¨â¶µÃöÁ䪺TARC(¯Ý¸¢¬¡¤Æ½Õ¸`ÁÍ ¤Æ¦]¤l)»PIgE(§K¬Ì²y³J¥ÕE)¥Í¤Æ«ü¼Ð¤W²§±`°¾§C¡A¥»¸ÕÅç2/3¨ü¸ÕªÌTARC°ò ½uȧC©ó700 pg/ml(Äv«~ÃĪ«Dupixent¦¬®×°ò½uȬ°1,953-6,147 pg/ml)¡B IgE°ò½u¥§¡È569 IU/ml(Dupixent¬°2,451-10,754 IU/ml)¡A¦]¦¹¡A§t¬A¤W z¤£²Å¦X¥Ø¼Ð±Ú¸s¨ü¸ÕªÌ«á¡A¥»¸ÕÅç¥Dnµû¦ô«ü¼ÐµLªk¹F¨ì²Îp·N¸q¡AµLªk ¶i¦æ³o¨Ç«D¥Ø¼Ð±Ú¸s¤§¨ü¸ÕªÌ¦³·N¸qµû¦ô¡C
¤@¤@¤@RITT ¤ÀªR
(b)¸g¶i¤@¨B¤ÀªR¡A©ó1/3¥Ø¼Ð±Ú¸s(TARC°ò½uȤj©ó700 pg/ml)ªºÃöÁäÀø®Ä«ü¼Ð EASI 75(²§¦ì©Ê¥Ö½§ª¢§ïµ½75%¡A¬°ÃÄ«~¤T´ÁÁ{§É¸ÕÅç¥DnÀø®Ä«ü¼Ð)¡A FB825¹F¨ì53.8%¡A¹ï·Ó²Õ¬°29.4%¡A»PÄv«~ÃĪ«Dupixentªº¨â¶µ¤T´Á¸ÕÅçµ² ªG44%¤Î51%¬Û·í¡C¤@¤@¤@¡]Dupilumab ¹ï·Ó²Õ 12%/15%) FB825©ó¥Ø¼Ð±Ú¸s¹F¨ì¹w´Á¤§¸ÕÅçªvÀø®ÄªG¡A¥i¤ä«ù¶i¦æ¡@ «áÄò¸ÕÅç¡C ¤@¤@¤@¤@¤@¤@ www.nejm.org/doi/full/10.1056/nejmoa1610020 ir.aslanpharma.com/static-files/662c1f39-bb78-4407-911d-19aa10cb1da6 ¤@¤@¤@¤@¤@ EASI75 Àø®ÄPK
Dupilumab¦©°£¹ï·Ó²Õ=32%¡ã36%¡]ITT) Dupilumab¦©°£¹ï·Ó²Õ¡×¬ù28%¡ã32%(RITT¡A¦©°£§CTRAC²Õ¡^
FB825¦©°£¹ï·Ó²Õ=24.4%(RITT)
ASLAN004 1b ¦©°£¹ï·Ó²Õ=54%(69%-15%=54%,N=16:13,RITT/¦©°£9¦ì«D¶Ç²ÎAD¤@§CTRAC¡^ ASLAN0041b ¦©°£¹ï·Ó²Õ=37%(50%-13%=37%¡]ITT N =22:16¡^ ¤@¤@¤@¤@¤@¤@¤@ µ²½×¡GY¨ÌRITT¤ÀªR ¡A¦©°£§CTRAC²ÕASLAN004 Àø®Ä¡A EASI75¡A¤j´T»â¥ý¨ä¥L¨âÃÄÁͶաI
EASI75(¦©°£¹ï·Ó²Õ)Àø®Ä ASLAN004 54% VS Dupilumab28%~32% VS FB825 24.4%
------------------- Y¨ÌITT¤ÀªR, EASI75(¦©°£¹ï·Ó²Õ)Àø®Ä ASLAN004 37% (P<0.05) VS Dupilumab32%~36% (P<0.05) VS FB825 <24% (©M¹ï·Ó²ÕµL²Îp¤Wªº©úÅã®t²§,p>0.05, )
---FB825 ¤é«á¥i¯à¦p²Ä¤@¥N¶·¨ÌÅ髤ÎIgE ¼Æ¶q°µ2b.¦ôpºCASLAN004 ¤@¦~.
¥H¤WADÁ{§É¼Æ¾Ú¤£¤ñ¸û,®³¤£¦P¤À¤l¨Ó»¡µü? ¯uÀ´·sÃħë¸ê??
¦]ªG¤£·À! ------------------------------------- ¬Ý¤£°_ASLAN004, ¥i¯à¥¢20¿Àò§Q¾÷·|(8/0.4=20),¤@¦~¤º. ----¦p¬ü°êú³°Ó8¬ü¤¸¥Ø¼Ð»ùpºâ.
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡GªL³Ò¬I10152784 |
µoªí®É¶¡:2022/5/26 ¤U¤È 07:29:49
²Ä 5341 ½g¦^À³
|
½Ð¥ý¦n¦n»¡»¡ ·íªìASLAN001¼Æ¾Ú¦h¦n, ³ø§i¦h¦n ¬°¦óÁÙ·|¥¢±Ñ¨ì¤¤¤î¶}µo?
ASLAN004¦p¦ó±¾«OÃÒ¤£·|«¨Ó¤@¦¸? |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡GªL³Ò¬I10152784 |
µoªí®É¶¡:2022/5/26 ¤U¤È 07:18:08
²Ä 5340 ½g¦^À³
|
ASLAN001 ·íªì¼Æ¾Ú¦hº}«G, ¼v¤ù¦h°Ê¤H ¨ì³Ì«á³£¦p¹Ú¦ü¤Û
¤j¦h¼Æ¤H³£¬O¬°¤FASLAN001 ¤j¹Ú ¶R¨È·à±d ¤j¨à¤lASLAN001 «±¤F, ¤~§â§Æ±æÂà¨ì¦Ñ¤GASLAN004
²{¦b¤j®a»{¬°ASLAN004 ªº¼Æ¾Ú»P³ø§i¦³¦h¦n, ¤@¼Ë¦p¹Ú¦ü¤Û ¦â§Y¬OªÅ! ¦³«Ü¦h¤º¹õ ¬O¤j®aµLªkª¾¹Dªº ³Ì«á¤]¦pASLAN001¯ë¥¢±Ñ ´N·Q·QASLAN001¬O«ç¼Ë¥¢±Ñ
¶R¨È·à±dn¤j¦¨¥\, ´N¦p¦P¤¤±m¨éÀY±m¤@¼Ëªº¤£¤Á¹ê»Ú ¤j®a¥iµ¥¤@¨â¦~«á, ¤T¤¦~«á´N¥iÅçÃÒ |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2022/5/26 ¤U¤È 06:34:54
²Ä 5339 ½g¦^À³
|
¦]ªG¤£·À!
©Ê¬Û¤@¦p!
¸Uªk¬ÒªÅ©ú¦ò©Ê.¤@¹Ð¤£¬VÃÒðÕ¤ß. |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¬õ¹Ð¦³¹Ú10150039 |
µoªí®É¶¡:2022/5/26 ¤U¤È 06:29:40
²Ä 5338 ½g¦^À³
|
¨ä¹ê²{¦bÁÙ«ù¦³¦Ñ·àªÑ²¼ªº·à¤Í ¤@©wµ{«×¤W³£¦³°µ¦n¥¢±Ñªº¤ß²z·Ç³Æ ´dÆ[ªºÄ±±o¦Û¤v¶Ì³QÄF¤W¸é²î¤F ¥i¬O¦b¶Ì¤]¤£¥i¯à½æ±¼¤F§ÖÅܾÀ¯ÈªºªÑ²¼ ¥h¶R³Q§j±·¨ì¤Ñ¤WªºªÑ²¼¡A¯à¶R´X±i ¯à¸Ñ¨M°ÝÃD¶Ü¡H 004¸Ñª¼¥¢±Ñ¾÷·|«Ü¤j¡A½Ð§â¼Æ¾Ú®³¥X¨Ó ¦Ñ·à¤Í¯à°í«ù¨ì²{¦b¾aªº¬O¼Æ¾Ú ¤£¬O¾a¼L¬¶¼Ú
´¼¼z¤£¶}¡A¦aº»¤£Ãö¡AµhW¤£Â_ |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2022/5/26 ¤U¤È 06:18:24
²Ä 5337 ½g¦^À³
|
YµL¤U¦C3ÃÄ,6Ó¤T´ÁADÁ{§É¸ê®Æ¦õµýMOA, ¯uªº¬ÝªÑ»ù·|没«H¤ß.
------------------------------------ ¬ÝÀ´¼v¤ù¤~¬Oªø§ë°ò¥»¥\,
ASLAN004 MOA -¼v¤ù aslanpharma.com/drug/aslan004/
2.Dupilumab MOA -¼v¤ù
www.dupixenthcp.com/atopicdermatitis/about/mechanism-of-action
MOA www.tsim.org.tw/journal/jour29-6/02.PDF?fbclid=IwAR2B85aLqBUAt5agx6K7u0NkCGTGpr7w6HDCagHhLuu54ZH7FEqHMAdXG3M ¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X ¤@¡BII«¬¨üÅé(TYPE II RECEPTER): ¡X¡X¹L±Ó©Êµoª¢¤ÏÀ³ ¸ô®|:
¤»Ó¥D¨¤: °tÅé : (1)IL-4(¤¶¥Õ¯À4¸¹) ,(2)IL-13 (¤¶¥Õ¯À13¸¹) ¨ü¾¹ : (3)IL-4R£\ , (4)IL-13 R£\1 (5)II«¬¨üÅé (TYPE II RECEPTER): (²Õ¦¨ A : IL4 ±µ¦XIL-4R£\ ¦A±µ¦X IL-13 R£\1) (²Õ¦¨ B : IL13 ±µ¦XIL-13R£\1 ¦A±µ¦X IL-4 R£\)
(6)pSTAT6
1. IL-4¤ÎIL-13 ¬Ò¥i ³y¦¨¹L±Ó©Êµoª¢¤ÏÀ³ , ¦³¥H¤UA¡BB¨â±ø¸ô®|
A: ¥ÑIL-4 ³y¦¨¹L±Ó©Êµoª¢¤ÏÀ³¸ô®|
¸ô®|(1). IL-4 ±µ¦X IL-4R£\ = IL4& IL-4R£\ (2). IL4& IL-4R£\ ¦A±µ¦X IL-13 R£\1=II «¬¨üÅé (²Õ¦¨II«¬ ¨üÅé) (3). II «¬¨üÅé±Ò°Ê²ÓM¤ºªº«H¸¹¶Ç»¼ (4). ¶i¦Ó¬¡¤ÆÂà¿ý¿E¬¡³J¥Õ6 (pSTAT6) (signal transducer and activator of transcription 6, pSTAT6) ¶Ç¾É¸ô®|, (5) ¾ÉP¹L±Ó©Êµoª¢¤ÏÀ³¡C
B: ¥ÑIL-13 ³y¦¨¹L±Ó©Êµoª¢¤ÏÀ³¸ô®|
¸ô®|(1). IL-13 ±µ¦X IL-13R£\1 = IL13& IL-13R£\1 (2). IL13 & IL-13R£\1 ¦A±µ¦X IL-4 R£\= II«¬ ¨üÅé (²Õ¦¨II «¬¨üÅé) (3). II «¬¨üÅé ±Ò°Ê²ÓM¤ºªº«H¸¹¶Ç»¼ (4). ¶i¦Ó¬¡¤ÆÂà¿ý¿E¬¡³J¥Õ6 (pSTAT6) (signal transducer and activator of transcription 6, pSTAT6) ¶Ç¾É¸ô®|, (5) ¾ÉP¹L±Ó©Êµoª¢¤ÏÀ³¡C ¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X- ¤G丶Dupilumab¤ÎASLAN004 ¬Ò¥i¦P®ÉªýÂ_IL4¤ÎIL13 °T®§¶Ç¾É¸ô®|
Dupilumab µ²¦XIL-4R£\ & ASLAN004 µ²¦XIL-13 R£\1¤§¾÷Âà(MOA) ¬Ò¥i¦P®ÉªýÂ_ II«¬¨üÅ餧²Õ¦¨¦ÓÁקKÂà¿ý¿E¬¡³J¥Õ6 (pSTAT6)¤§¬¡¤Æ¡A¤]ÁקK¹L±Ó©Êµoª¢¤ÏÀ³. ¨Ï±oA&B ¸ô®|¤¤¤£²£¥Í(2)~(5)¸ô®|¡C
¤T¡BLebrikizumab & Tralokinumab M〇A , ¥u¯àªýÂ_IL13 °T¸¹¶Ç»¼¡AµLªk§¹¥þªýÂ_IL4 °T¸¹¶Ç»¼¡A¥\¯à¤j´î75%~50%¡C
µLªkªýÂ_ A¸ô®| (2): IL4 & IL-4R£\ ¦A±µ¦XIL-13R£\1 , ²Õ¦¨ªºII«¬¨üÅé, ¦]¦Ó±Ò°Ê²ÓM¤ºªº«H¸¹¶Ç»¼¡A¶i¦Ó¬¡¤ÆÂà¿ý¿E¬¡³J¥Õ6 (signal transducer and activator of transcription 6, STAT6) ¶Ç¾É¸ô®|,¾ÉP¹L±Ó©Êµoª¢¤ÏÀ³¡C
¥u¯àªýÂ_B¸ô®| : Lebrikizumab ±µ¦X IL13 ªºB¡BCÁ³±Û , ¦ýIL13 & IL-13R£\1 ¤´¥i±µ¦X¡A¥u¬OµLªk¦A±µ¦X IL-4 R£\,µLªk²Õ¦¨ II«¬ ¨üÅé Tralokinumab ±µ¦XIL13 ªºA¡BDÁ³±Û ¨Ï IL13 & IL-13R£\1 µLªk±µ¦X¡A¤]µLªk¦A±µ¦X IL-4 R£\,µLªk²Õ¦¨ II «¬¨üÅé
¥H¤W¸ÑÄÀ Tralokinumab ¤T´ÁÁ{§É¹w«á«ü¼Ð¡AÀø®Ä´X¥G¥u¦³Dupilumab 50%¡C
¦]Lebrikizumab , IL13 & IL-13R£\1 ¤´¥i±µ¦X¦û¾Ú IL-13R £\1, ¼vÅT0~50% IL4 °T¸¹¶Ç»¼¡C ¤]¸ÑÄÀ Lebrikizumab ¤G´ÁÁ{§É¹w«á¥Dn«ü¼Ð»P¹ï·Ó²Õ¤ñ È ¥u¦³Dupilumab 50%~75% |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2022/5/26 ¤U¤È 06:05:41
²Ä 5336 ½g¦^À³
|
©ú©ú¬OFB825 2A¸Ñª¼,¥Dn«ü¼ÐPÈ¥¼¹F¼Ð. FB825 2A ¥h°£2/3«á«D¥Ø¼Ð±wªÌ«á, Àø®ÄEASI75 ¦©°£¹ï·Ó²Õ¶È°ª¥X24%. ¦b¤w°µ§¹2´Á·sÃĤΫJ¿ïªÌ¤¤,¥uĹLEOªºtralokinumab.
LEO ÁÙn°µSC VS IV ¾ô±µ,ÁÙn§ä¥Ø¼Ð«È¤á.
³º»¡¦³«H¤ß.¯¬ºÖ¦³«H¤ßªÌ.
www.marketbeat.com/stocks/NASDAQ/AS LN/price-target/
¬ü°ê(¥|®a)ú³°Óµ¹ASLN ¤@¦~ªº¥Ø¼Ð»ù(¾ú¥v)
1.5/23/2022 HC Wainwright 8¬ü¤¸/ªÑ(³Ì·s³ø§i,ºû«ù¥Ø¼Ð»ù) 2.5/23/2022 Piper Sandler 3¬ü¤¸/ªÑ(³Ì·s³ø§i,±q8¬ü¤¸°¬°3¬ü¤¸)
³o¬O¤½¶}¥«³õ¶Ò¸êú³°Ó5/23³Ì·s³ø§i.
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡GªL³Ò¬I10152784 |
µoªí®É¶¡:2022/5/26 ¤U¤È 05:10:35
²Ä 5335 ½g¦^À³
|
¬Ý¤F¦n¦h½g ³o¸Ì¥u¦³©ú¤Ñ¹L«á¤j¬O²M¿ôªº ¥u¦³¥Lµo²{¨È·à±dªº¯u¬Û ¯u¬Û¬OÅã¦Ó©ö¨£ªº
³o¸Ì¤j©@ªø´Á¹ïASLAN-001¦h©Ò§j±·, ¤Þ¥Î¤j¶q¼Æ¾Ú, ¤ÀªR¤F¦n´X¦~ ¤@¶}©l¨Ó¬Ýªººô¤Í·|¤j¶}²´¬É, ¥E¬Ý¤§¤U, ·|·Q»¡«ç»ò¦³±M·~ªº? ·|«Ü®e©ö³Q§l¤Þ·Q¥h¶R³o®aªÑ²¼
µo²{¤]¤£¹L¬O¹ï¥¢±Ñªº«áª¾«áı¿ù»~¸ÑŪ¼Æ¾Ú
¦A¤Þ¥Î°ª¹¬ÁI®võ²z¬°¦Û¤v°õ°g¤£®©¨ì¥¢±Ñ¶}²æ
Ä~Äò¤U¤@¥Ø¼Ð¹ï«áÄòASLAN-004°õ°g¤£®© Ä~Äò¤j¶q¸ÑŪ¼Æ¾Ú, Ä~Äò¤£¤Á¹ê»Úªº¹Ú
¦ò®a¤£´N¬O¤£¦k»y, ¤£°õ©À µ²ªGªø´Á¥H¨Ó¬Ò¤Ï¨ä¹D¦Ó¦æ ³o¤£¬O¹HI¤F¤»¯ªªººë¯«?
ASLAN-004¸Ñª¼¥¢±Ñ¾÷²v·¥°ª, ½Ñ¦h¸ñ¶H¥i¬Ý¥X(½Ð°Ñ¦ÒASLAN-001¥¢±Ñ¹Lµ{) ½Ð¤£n¦A°µ¤£¤Á¹ê»Úªº¹Ú¤F
¬Ý¦nASLAN-004ÁÙ¤£¦p¬Ý¦n¦X¤@ªºon101¥Ö½§ÃÄ ÁöµMon101§Ú¬ÝÃa, ASLAN-004¬O·¥«×¬ÝÃa ASLAN-004ÃÄÃÒ¹LÃö ¦³¦p¤Ó¶§¥´¦è¤è¤É°_
§Æ±æ¥»½g¤å³¹¤j®a¥i¥H³Æ¥÷°_¨Ó ©Î§Æ±æ¼Ó¥D¨{¶q¯à¼µ²î
µ¥¨ìASLAN-004¸Ñª¼µ²ªG«á
©Î¬O¼µ¤£¨ì±ÂÅv, ´N¤¤¤î¶}µo
¨ÓÅçÃÒ¬O§_¯u¦p¦P©ÒÁ¿¤£¬Ý¦n ¦A§R¦A«Ê¤]¤£¿ð! |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2022/5/26 ¤W¤È 10:43:07
²Ä 5334 ½g¦^À³
|
www.marketbeat.com/stocks/NASDAQ/ASLN/price-target/
¬ü°ê(¥|®a)ú³°Óµ¹ASLN ¤@¦~ªº¥Ø¼Ð»ù(¾ú¥v)
1.5/23/2022 HC Wainwright 8¬ü¤¸/ªÑ(³Ì·s³ø§i,ºû«ù¥Ø¼Ð»ù) 2.5/23/2022 Piper Sandler 3¬ü¤¸/ªÑ(³Ì·s³ø§i,±q8¬ü¤¸°¬°3¬ü¤¸) ------------------------------------------------------------ 3.7/9/2021 Jefferies Financial Group 8¬ü¤¸/ªÑ 4.12/2/2019 Piper Jaffray Companies 8¬ü¤¸/ªÑ
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2022/5/26 ¤W¤È 10:18:20
²Ä 5333 ½g¦^À³
|
Lebrikizumab 2bÁ{§É,°ò½u¶}©l«eªº¤H¿ï¿z¿ï¥h°£²v51%
www.ncbi.nlm.nih.gov/pmc/articles/PMC7142380/
424 ¤H°Ñ¥[¿z¿ï ,280¤H¶i¤J¤G´ÁÅç§ÉªºÀH¾÷¤À°t, ¥h°£²v : (424-280)/280=51%
¯uªºÄY®æ¿z¿ï.
---------------------------------------- ·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2022/5/15 ¤U¤È 07:17:40²Ä 5310 ½g¦^À³ Dupilumab 2Ó¤T´ÁÁ{§É,°ò½u¶}©l«e35¤Ñ¶¡ªº¤H¿ï¿z¿ï¥h°£²v36.3%
1.SOLO1 ,Out of 917 participants, 671 were randomized (¿z¿ï¥h°£±¼917-671=246¤H, ¥h°£²v36.6%) 2.SOLO2, Out of 962 participants, 708 were randomized (¿z¿ï¥h°£±¼962-708=254¤H, ¥h°£²v35.8%) ¤pp 1879 ¤H°Ñ¥[¿z¿ï ,1379¤H¶i¤J¤T´ÁÅç§ÉªºÀH¾÷¤À°t, ¥h°£²v: (1879-1379)/1379=36.3%
Study of Dupilumab Monotherapy Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis (SOLO 1) clinicaltrials.gov/ct2/show/results/NCT02277743
Study of Dupilumab (REGN668/SAR231893) Monotherapy Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis (SOLO 2) clinicaltrials.gov/ct2/show/results/NCT02277769
SOLO1
Out of 917 participants, 671 were randomized and 669 were treated in the study.
Participants were randomized in 1:1:1 ratio to receive Dupilumab 300 mg once weekly (qw), Dupilumab 300 mg every 2 weeks (q2w) or Placebo qw
SOLO2
Recruitment Details The study was conducted in 10 countries between 03 December 2014 and 21 January 2016. A total of 962 participants were screened in the study. Pre-assignment Details Out of 962 participants, 708 were randomized and 707 were treated in the study. Participants were randomized in 1:1:1 ratio to receive Dupilumab 300 mg once weekly (qw), Dupilumab 300 mg every 2 weeks (q2w) or Placebo qw. |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G³¯¤p©ú10152293 |
µoªí®É¶¡:2022/5/23 ¤U¤È 12:06:44
²Ä 5332 ½g¦^À³
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2022/5/23 ¤W¤È 11:15:46
²Ä 5331 ½g¦^À³
|
whalewisdom.com/stock/asln
2022¦~3¤ë31¤é«ùªÑ
²H°¨¿ü没ÅÜ. Àq§J(¤¤°ê),¤£¦b¦¹ªí.¦]¬°¤£¬O¦b¬ü°êµù¥U¤½¥q.
²Ä¤@©u¬ü°ê¾÷ºc½æ¥X>¶R¶i¬ù1000¤dªÑ. ³Ì¤j¶R¶iªÌ¬O¥Ø«e«ùªÑ5.6%,²Ä¤@ªºTANG CAPITAL MANAGEMENT LLC, ¬ù3700¤dªÑ. ¥»©u¼W¥[¬ù1700¤dªÑADR
«ùªÑ«e10 ¦Wªº¬üªÑ¾÷ºc TANG CAPITAL MANAGEMENT LLC 3,759,225 (¥»ºô©Ò¸ü¬°´¶³qªÑªÑ¼Æ18,796,125,°£5=3,759,225) RTW INVESTMENTS, LP 3,250,000 VIVO CAPITAL, LLC 2,840,909 CITADEL ADVISORS LLC 2,700,902 MANGROVE PARTNERS 1,942,491 ORBIMED ADVISORS LLC 1,941,219 TEMASEK HOLDINGS (PRIVATE) LTD 1,678,075(²H°¨¿ü«ùªÑ没ÅÜ) MILLENNIUM MANAGEMENT LLC 1,569,164 SIO CAPITAL MANAGEMENT, LLC 1,270,758 IKARIAN CAPITAL, LLC 970,747 |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G³¯¤p©ú10152293 |
µoªí®É¶¡:2022/5/23 ¤W¤È 11:01:41
²Ä 5330 ½g¦^À³
|
¯à§_½Ð¤Ñ©R¤j ¤ÀªR¤@¤U¨È·à±d¬OªÑ²¼Äw½X¤À¥¬±¡§Î¡A ¤Î³Ìªñ¥Dn«ù¦³ªÌ«ùªÑ¼W´îÃB¡A ·Q¤F¸Ñ¤jªÑªF·s¥[©Y¬F©²°òª÷©Î²H°¨¿ü¡BÀq§J«ùªÑ¬O§_ÃP°Ê |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2022/5/23 ¤W¤È 09:04:01
²Ä 5329 ½g¦^À³
|
¤@¡BLebrikizumab(16¶g),¤T´Áªº¨âÓÁ{§É
In ADvocate 1,
(IGA) 43%-13%=30% EASI 59%-16%=43%
In ADvocate 2,
(IGA) 33%-11%=22% EASI75 51%-18%=33%
¤G¡BASLAN004 (8¶g)1b¡A¡K¡K¼ÒÀÀ2b¡A16¶g
EASI75 69%-15%(¹ï·Ó²Õ)=54% (IGA) 53%-12%(¹ï·Ó组)=41%
¤T¡BASLAN004 2b vs Lebrikizumab
1. ASLAN004 Vs ADvocat1 EASI75 54% VS 43%, (54%/43%=126%) (IGA) 41% VS 30%, (41%/30%=137%)
2.ASLAN004 VS ADvocat2 EASI75 54% VS 33%,(54%/33%=164%) (IGA) 41% VS 22%,(41%/22%=186%)
¥|¡Aµ²½×¡ALebrekizumab MOA³y¦¨¹ïIL4ªº资°T¶Ç»¼¡A®É¦³®ÉµL¡C³y¦¨2ÓAD¤T´ÁÀø®Ä®É¦n®É®tª¬ºA¡C
¦bý³Ý¤T´Áªº2ÓÁ{§É¤]§e²{¡A¥Dn«ü¼Ð¤@ÓPÈ<0.05¡A¥t¤@Ó>0.05ªºª¬ºA¡A¦Ó¤¤¤î¬ã¨s¡C
¤¡B¨Ì¾ÚLebrekizumab ³Q§ª«¨Ó¨ÖÁÊ»ù11»õ¬ü¤¸¡C
¥¼¨Ó¨ÖÁʵo¥Í,¥i¯à¦X¬ù: ¦ôp¤Î±ø¥ó
11/50*145*2=64»õ¬ü¤¸(¨È·à¿W±o)
Lebrikizumab AD³Q¨Ö»ù11»õ¬ü¤¸/2019¦~dupilumab 50»õ¬ü¤¸³Ì°ª¾P°â¹w´ú*2022¦~dupilumab 145»õ¬ü¤¸³Ì°ª¾P°â¹w´ú *2 ¿(¨ä¥L004¾AÀ³¯gý³Ý/COPD/EOE...¤ÎASLAN003»ùÈ.)
¡X¡X¦ô2023¦~¤U¥b¦~«áÀH®É¯àµo¥Í --¨ÖÁʪ̥t¶·¤ä¥ICSL¤W´å¦X¬ù.
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¸Ø±i10133098 |
µoªí®É¶¡:2022/5/22 ¤W¤È 11:25:35
²Ä 5328 ½g¦^À³
|
¤U§«ôÀ³¸Ó·|¤½§i¦¬®×¤¤¤ß¦¨¥ß¶i«×¡A¹w´ÁÁ`¼ÆÀ³¸Ó·|¶W¹L50Ó¡C |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G³¯¤p©ú10152293 |
µoªí®É¶¡:2022/5/21 ¤W¤È 09:44:47
²Ä 5327 ½g¦^À³
|
Aslan±q¥h¦~9¤ë24¤é¡A3.25¤¸¤U¶^¦Ü¤µè¦n8Ó¤ë¡A¶^±¼86.2% ¥Ø«e¦]¤½¥q¤@¦A»¡©úib¼Æ¾Ú¡A¦³¼È®É¤î¶^¿v©³²{¶H¡A §Æ±æ¤£n¦A©¹0.2¯}©³ ·PÁ¦U¬°¥Î¤ß¤À¨É ²{¦b¥u¯àÀR«Ý2b´Á¤¤¼Æ¾Ú©Î¸Ñª¼
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2022/5/21 ¤W¤È 08:08:30
²Ä 5326 ½g¦^À³
|
¤@.Lebrikizumab(16¶g)¤T´Á
In ADvocate 1,
(IGA) 43%-13%=30% EASI75 59%-16%=43%
¤G¡BASLAN004 (8¶g)1b¡A¡K¡K¼ÒÀÀ2b¡A16¶g
EASI75 69%-15%(¹ï·Ó²Õ)=54% (IGA) 53%-12%(¹ï·Ó组)=41%
¤T¡BASLAN004 2b vs Dupilumab ¤T´Á ¦©°£¹ï·Ó组«áªºPK EASI75 54% vs 36%(54%/36%=150%) (IGA) 41% vs 28% (41%/28%=146%)
ASLAN004 ±N¤j´TÀu©óDupilumabªºÁͶաC
¥H¤WÓ¤H¼ÒÀÀ
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2022/5/21 ¤W¤È 07:48:28
²Ä 5325 ½g¦^À³
|
¨ÌASLAN004 ¯à¦P®Éªý断IL4/IL13 ªºMOA¡A²z½×¤WÀø®Ä 赢¹LLebrikizumab ¤T´Áªºªí²{¡C
2b ¤½¥qµ´¹ï·|¦b¶i¤JÁ{§É«eç°£«D¶Ç²ÎAD(§CTRAC/§CIgE/§CEASI/µL¨Öµo¯g)
Àu©ó¤½¥q²³ø¤¤ªº±Ó·P«×¤ÀªRÀø®Ä¾÷·|°ª¡C
¡G¤Ñ©R10141925 µoªí®É¶¡:2022/4/4 ¤U¤È 10:20:46²Ä 169 ½g¦^À³ Ó¤H¬Ýªk
Lebrikizumab(16¶g) VS Dupilumab(¤T´Á ¼Æ¾Ú¦©°£¹ï·Ó²Õ )
¦n®ø®§¬O§@¥Î¦bIL13 Lebrikizumab ¤T´Á(16¶g) ¥X²{¤@¥b¾÷·|¥i¯àÀu©óDupilumab ¤T´Á.
Lebrikizumab MOA : ±µ¦X IL13 ªºB¡BCÁ³±Û , IL13 & IL-13R£\1 ¤´¥i±µ¦X¡A¥u¬OµLªk¦A±µ¦X IL-4 R£\, ¥iªý¤îIL13°T¸¹¶Ç»¼.
¦ýLebrikizumab , IL13 & IL-13R£\1 ±µ¦X¦û¾Ú ³¡¥÷IL-13R £\1, ¼vÅT³¡¥÷ IL4 °T¸¹¶Ç»¼¡C IL-13R £\1¥¼³Q¦û¾ÚªÌ,IL4°T¸¹¯à³Q¶Ç»¼¨ìTYPE II recepter ,¦Ó¨Ï¡«á°ªÀø®ÄÅÜ®t.
------------------------ ASLAN004 MOA ±µ¦X IL-13R£\1 ,¥i±æ¦³¾÷·|§óéwªºÂ¡«á°ªÀø®Ä, Àu©óLebrikizumab(16¶g)In ADvocate 1 ¾÷·|°ª.
------------------------------------------
¤@.Lebrikizumab(16¶g)
In ADvocate 1,
(IGA) 43%-13%=30% EASI 59%-16%-43%
In ADvocate 2,
(IGA) 33%-11%=22% EASI75 51%-18%=33%
¤G.Dupilumab ¤T´Á(16¶g) In SOLO 1,
(IGA) 38%-10%=28% EASI75 51%-15%=36%
In SOLO2 2,
(IGA) 36%-8%=28% EASI75 44%-12%=32%
----------------------------------
Lebrikizumab ¤GÓ¤T´Á¥Dn«ü¼Ð16¶g¡«áÀø®Ä¡C¤@¤@¤@¤@2022AAD¦~·|¤fÀY³ø§i
In ADvocate 1, 43 percent of patients receiving lebrikizumab achieved clear or almost clear skin (IGA) at 16 weeks compared to 13 percent of patients taking placebo. Among those receiving lebrikizumab, 59 percent achieved an EASI-75 response, compared to 16 percent with placebo.
In ADvocate 2, 33 percent of patients taking lebrikizumab achieved clear or almost clear skin (IGA) at 16 weeks, compared to 11 percent of patients on placebo. Among those receiving lebrikizumab, 51 percent achieved an EASI-75 response, compared to 18 percent taking placebo.
www.nejm.org/doi/full/10.1056/nejmoa1610020 |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¬õ¹Ð¦³¹Ú10150039 |
µoªí®É¶¡:2022/5/21 ¤W¤È 07:37:25
²Ä 5324 ½g¦^À³
|
¤â¤Wªº²{ª÷§Ö¥Î¥ú¤F ¨®¤lÀ³¸ÓÁÙ¯à·dÓ2.30¸U ¦³ºØ¶^¨ì2¤¸¡A§Ú®³©Ð¤l¸ò§A½ä ºÎ¤½¶é¡A¾Ç®Õ©ÎÅܦ¨¨â¶¡©Ð¤l°µ¥]¯²¤½ |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡GDHL10147526 |
µoªí®É¶¡:2022/5/21 ¤W¤È 07:37:05
²Ä 5323 ½g¦^À³
|
ÁÂÁ¤ѩR¤jªº¤À¨É ´Á«Ý2b¥i¥H¦³¦nµ²ªG. 継Äò°lÂܬݤU¥h. |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2022/5/21 ¤W¤È 07:20:51
²Ä 5322 ½g¦^À³
|
DHL ¤j¡A 2b Y¯à赢¹LDupilumab Àø®Ä20%¡A¥«³õ¶Ò资¸û¦n¹F¦¨¡A 70»õ¬ü¤¸ªº³Ì°ª¾P°â谮¤O¡A³Q¨Ö»ùÈ°ª¡C
¦Ü©ó¥|©P¤@°w¡A¥«³õ»ùÈ¡A´N¬Ý¥¼¨Ó¤T´ÁÁ{§É³]p¡A¬O§_n¥[¥|¶g¤@针¡A2Ó3´Áx200¤H=400¤H¡A¤½¥qµû¦ôYȱo°µ¤~·|Ä~Äò¡C
¥i¯à·|¦³16-52¶gªº©µ¦ùªº¤T´ÁÁ{§É¡Cx2Ó¤T´Á
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡GDHL10147526 |
µoªí®É¶¡:2022/5/21 ¤W¤È 06:48:33
²Ä 5321 ½g¦^À³
|
§Ú³ßÅw¬Ý¨ì¦³¤H¤@ª½´£¿ô·ÀI¡A ³o¼Ë¤~·|¦³¥þ±«ä¦Ò¡A ÁÂÁ¡¦©ú¤Ñ¹L«á¡¦ ¤j ³o¼Ë¯uªº½ß¿ú¡AÁÈ¿ú¡A³£¬O¦ÛÄ@ªº¡C
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡GDHL10147526 |
µoªí®É¶¡:2022/5/21 ¤W¤È 06:35:36
²Ä 5320 ½g¦^À³
|
½Ð±Ð¤@¤U¤Ñ©R¤j¤j¡G ²³ø¤¤ 1.However, only 8% of eligible patients receive dupilimab today2 and there remains a significant unmet need: ¡V Only 35% of patients treated with dupilumab achieved an optimal response1 ASN004 ·|¦³¤£¤@®Äªº®ÄªG¡H¥i¥Hªv¨ä¥¦65¢H 2. ¬O§_¥i¥H¬Ý¥X4¶g¤@°w·|¦¨¥\¡H·|¦³¦nªºÀø®Ä¡C
¤£ª¾¹D¤Ñ©R¤j¬O§_¬ã¨s¹L³o¨âÃD¡H¦pªG¦³¡A¬O§_¥i¥H¤À¨É¬Ýªk ·P®¦¡I |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G©ú¤Ñ¹L«á10151242 |
µoªí®É¶¡:2022/5/21 ¤W¤È 06:25:20
²Ä 5319 ½g¦^À³
|
¤£ºÞ¬O¤°»òª¯§¾¼Æ¾Ú¡A³oÃ䪺¬Y¨Ç¤H³£·|¸ÑŪ¦¨¶W¯ÅÀu¡A·Ç³Æn³Q´X¤Q»õ¬üª÷¦¬Áʪº¬~¸£¤å¶}©l³sµo¡AC....²{¦b¦n¹³¥«È¥u¦³3¤d¸U¬üª÷C¡I ¥Ø¼Ð»ù0.2¦rÀY¶}©l±Ò°Ê¡A¤£¬Û«H¶Ü¡Aµ¥µÛ¬Ý§a¡I |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¿ûÅK¨k¤l10144826 |
µoªí®É¶¡:2022/5/21 ¤W¤È 01:17:32
²Ä 5318 ½g¦^À³
|
¯u¦p²³ø©Òz¦p¦¹ªºÀu¨q¡H ¨ºªÑ»ù¦ó®É¤~·|¤ÏÀ³°Ú¡H |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2022/5/20 ¤U¤È 09:00:48
²Ä 5317 ½g¦^À³
|
ir.aslanpharma.com/static-files/20941066-3bc3-418b-a970-9951565de0f2 ¤½¥q²¤¶p19
Mean change in peak P-NRS from baseline 600mgX8¶g¡C Percentage change from baseline in the Pruritus Numerical Rating Scale (NRS) score weekly up to Week 8.
¹êÅç²Õ 37% VS 16% P=0.032
¤µ¤Ñ¤½§G³ø§i
»P¹ï·Ó±ø¥ó¬Û¤ñ¡AEblasakimab ÅãµÛ°§C¤F²ÓM¦]¤l¼W±jªº¯«¸g¤¸¹ï IL-4 ©M IL-13 ÅX°Êªºæ±Äoªº¤ÏÀ³¶W¹L 40% (p=0.0001)2¡A³oªí©ú eblasakimab ªýÂ_ IL-13R£\1 ªº¿W¯S¾÷¨î¥i¥H´£¨Ñ¤À¤l°ò¦¦b 1b ´ÁÁ{§É¸ÕÅ礤¡A¦b eblasakimab ªvÀøªº¤¤«×¦Ü««× AD ±wªÌ¤¤Æ[¹î¨ìªºæ±Äoµû¤ÀÅãµÛ°§C¡C
Xx ¥i¯à¬Olb Æ[¹î¨ì16¶gªº·s¼Æ¾Ú¡A¡H¡I |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G³¯¤p©ú10152293 |
µoªí®É¶¡:2022/5/20 ¤U¤È 08:54:21
²Ä 5316 ½g¦^À³
|
¥[§QºÖ¥§¨È¦{ªù¬¥©¬§J©M·s¥[©Y¡A2022 ¦~ 5 ¤ë 20 ¤é (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq: ASLN) ¬O¤@®aÁ{§É¶¥¬q¡B¥H§K¬Ì¾Ç¬°«ÂIªº¥Íª«»sÃĤ½¥q¡A¶}µo³Ð·sÀøªk¥H§ïÅܱwªÌªº¥Í¬¡¡A¤µ¤Ñ«Å¥¬¤FºtÁ¿¦b¥Ö½§¯f¾Ç¬ã¨s¨ó·| (SID) ¦~·|¤W¡A³q¹L eblasakimab ¹v¦V IL-13R£\1 ¬ð¥XÅã¥Ü»P¯«¸g¤¸æ±Äo¾÷¨î¬ÛÃöªº·s¼Æ¾Ú©M¨£¸Ñªº®ü³ø¡C³o¨Ç¼Æ¾Ú¥Ñ ASLAN Âà¤Æ¬ì¾Çt³d¤H Ferda Cevikbas ³Õ¤h´£¨Ñ¡C
ºC©Êæ±Äo¬O¯SÀ³©Ê¥Öª¢©M¨ä¥L tType 2 ÅX°Êªºª¢¯g©Ê¥Ö½§¯fªº¼Ð»x©M¥Dn¯gª¬¡C³Ìªñ±À´ú¡A¯SÀ³©Ê¥Öª¢ (AD) ¤¤ªºæ±Äo«H¸¹·|¦]¥Ö½§¤¤¦s¦bªº«Pª¢²ÓM¦]¤l¦Ó¥[¼@ 1¡A±q¦Ó¾ÉP§K¬Ì¤ÏÀ³¯}Ãa¥Ö½§«Ì»Ù¨ÃÅX°Ê¯e¯f¯f²z¡C¦b§Ú̪º¬ã¨s¤¤¡A§Ú̪í©ú IL-13 ©M IL-4 §@¬°¯«¸g¤¸¼W±j¾¯¡A³q¹L 2 «¬¨üÅ骺 IL-13R£\1 ¨È°ò©ñ¤jæ±Äo³~®|¡A¨Ã¥B³o¨Ç§@¥Î¥i¥H³Q¨Ì¥¬©Ô³ß³æ§Ü§í¨î¡C
ASLAN Pharmaceuticals º®uÂåÀø©x Alexandre Khaoukhov ³Õ¤hµû½×»¡¡G¡§°£¤F¦b¯SÀ³©Ê¥Öª¢±wªÌ¤¤¬Ý¨ìªº¯kµh¡Bµoª¢ªº¥Ö½§·l¶Ë¥~¡AºC©Êæ±Äo¥i¯à·|¥[«³oºØ¯e¯fªº¾ãÅét¾á¡AÄY«¼vÅT¥Í¬¡½è¶q¡C³o¨Ç¼Æ¾Ú´yø¤F eblasakimab ¦b´î¤Öæ±Äo©Ê¯«¸g¤¸¤ÏÀ³¤¤ªº§@¥Îªº¥O¤H¹ª»Rªºµe±¡A¨Ã¼W¥[¤F§Ú̹ï eblasakimab ¿W¯S§@¥Î¾÷¨îªº¯q³Bªº²z¸Ñ¡A§Y³q¹L 2 «¬¨üÅéÂù«ªýÂ_ IL-4 ©M IL-13¡C¡¨
µo¥¬¸Ô±¡ ÃD¬°¡§¥Î¨Ì¥¬©Ô¨ä³æ§Ü¹v¦V IL-13R£\1 ¹ï¯«¸g¤¸æ±Äo¾÷¨îªº·s¨£¸Ñ¡¨ªº®ü³ø®i¥Ü¤F¤HÃþI®Ú¯«¸g¸` (hDRG) ¯«¸g¤¸¦b¥Î¨Ì¥¬©Ô¨ä³æ§Ü¡B³æ¿Wªº IL-4¡BIL- ¹w³B²z«áªºÂ÷Åé¬ã¨sµ²ªG¡C 13 ³æ¿W©Î IL-4 ©M IL-13 ªº²Õ¦X¡C³q¹L¬¡²ÓM¶t¦¨¹³®·Àò¯«¸g¤¸¤ÏÀ³¡C
»P¹ï·Ó±ø¥ó¬Û¤ñ¡AEblasakimab ÅãµÛ°§C¤F²ÓM¦]¤l¼W±jªº¯«¸g¤¸¹ï IL-4 ©M IL-13 ÅX°Êªºæ±Äoªº¤ÏÀ³¶W¹L 40% (p=0.0001)2¡A³oªí©ú eblasakimab ªýÂ_ IL-13R£\1 ªº¿W¯S¾÷¨î¥i¥H´£¨Ñ¤À¤l°ò¦¦b 1b ´ÁÁ{§É¸ÕÅ礤¡A¦b eblasakimab ªvÀøªº¤¤«×¦Ü««× AD ±wªÌ¤¤Æ[¹î¨ìªºæ±Äoµû¤ÀÅãµÛ°§C¡C
Ãö©ó eblasakimab Eblasakimab ¬O¤@ºØ¼ç¦bªº¤@¬yªº¹v¦V IL-13 ¨üÅ骺³æ§J¶©§ÜÅé¡A¦³¥i¯à¬°±wªÌ´£¨Ñ®t²§¤Æªº¦w¥þ©Ê©M¦³®Ä©Ê¥H¤Î§ï¶iªºµ¹ÃĤè®×¡C 2021 ¦~ 9 ¤ë¡AASLAN «Å¥¬¤F 1b ´Á¦h¦¸»¼¼W¾¯¶q¬ã¨sªº¿n·¥µ²ªG¡A¸Ó¬ã¨s½T¥ß¤F ASLAN004 ªº·§©ÀÃÒ©ú¡A¨Ã¤ä«ù¨ä§@¬° AD ·sÀøªkªº¼ç¤O¡C 2022 ¦~ 1 ¤ë¡A¨È·à±d±Ò°Ê TREK-AD 2b ´Á¸ÕÅç¡A¥Hµû¦ô eblasakimab ¦b¤¤«×¦Ü««× AD ±wªÌ¤¤ªº¦w¥þ©Ê©M¦³®Ä©Ê¡C |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2022/5/20 ¤U¤È 07:24:13
²Ä 5315 ½g¦^À³
|
ASLAN Pharmaceuticals Presents Late-Breaking Poster on Eblasakimab and Neuronal Itch Mechanisms at the 2022 Society for Investigative Dermatology Annual Meeting
½×¤å细¸`
¥D题¬° New insights into neuronal itch mechanisms by targeting IL-13R£\1 with eblasakimab ªº®ü报®i¥Ü¤F¤HÃþI®Ú¯«¸g¸`¡]hDRG¡^¯«¸g¤¸¸geblasakimab¡B单独IL-4¡B单独IL-13©ÎIL-4©MIL-13组¦X预³B²z«áªºÅé¥~¬ã¨s结ªG¡C³q¹L¬¡细M¶t质¦¨¹³®·®»¯«经¤¸ªº¤Ï应¡C
Eblasakimab©ú显ú£¤Ö¤F细M¦]¤l¼WüLªº¯«¸g¤¸¹ïIL-4©MIL-13驱动ªºæ±Ö}¤ÏÀ³¡A»P¹ï·Ó²Õ¬Û¤ñú£¤Ö¤F40%¥H¤W¡]p=0.0001¡^2¡A这ªí©úEblasakimabªý断IL-13R£\1ªº¿W¯S¾÷¨î¥i¥H¬°1b´ÁÁ{§É试验¤¤观¹î¨ìªºEblasakimabªv疗ªº¤¤««×AD±wªÌæ±Ö}评¤Àªº©ú显ú£¤Ö´£¨Ñ¤À¤l°ò础¡C
Publication details The poster titled, ¡§New insights into neuronal itch mechanisms by targeting IL-13R£\1 with eblasakimab¡¨ presents results from an ex vivo study in human dorsal root ganglia (hDRG) neurons after being pre-treated with eblasakimab, IL-4 alone, IL-13 alone or a combination of both IL-4 and IL-13. Neuronal responses were captured by live cell calcium imaging.
Eblasakimab significantly reduced cytokine-enhanced neuronal responses to IL-4 and IL-13-driven itch by more than 40% versus control conditions (p=0.0001)2, suggesting eblasakimab¡¦s unique mechanism of blocking IL-13R£\1 could provide a molecular basis for the significant reduction of pruritis scores observed in eblasakimab-treated moderate-to-severe AD patients in the Phase 1b clinical trial.
finance.yahoo.com/news/aslan-pharmaceuticals-presents-breaking-poster-110000795.html
MENLO PARK, Calif. and SINGAPORE, May 20, 2022 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq: ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced the presentation of a poster highlighting new data and insights related to neuronal itch mechanisms through eblasakimab¡¦s targeting of IL-13R£\1 at the Society for Investigative Dermatology (SID) Annual Meeting. The data were presented by Ferda Cevikbas PhD, Head of Translational Sciences at ASLAN.
Chronic itch is a hallmark and major symptom of atopic dermatitis and other tType 2-driven inflammatory skin disorders. Itch signaling in atopic dermatitis (AD) has been recently postulated to be exacerbated by pro-inflammatory cytokines present in the skin1, causing an immune response that disrupts the skin barrier and drives disease pathology. In our study, we show that IL-13 and IL-4 act as neuronal enhancers for the amplification of itch pathways through the IL-13R£\1 subunit of the Type-2 receptor and these effects can be inhibited by eblasakimab.
Dr Alexandre Khaoukhov, Chief Medical Officer, ASLAN Pharmaceuticals, commented: ¡§Aside from the painful, inflamed skin lesions seen in patients with atopic dermatitis, chronic itch can be a debilitating addition to the overall burden of this disease, significantly impairing quality of life. These data paint an encouraging picture of eblasakimab¡¦s role in reducing pruritic neuronal responses and add to our understanding of the benefits of eblasakimab¡¦s unique mechanism of action in its dual blockade of both IL-4 and IL-13 through the Type 2 receptor.¡¨
ASLAN¨î药¤½¥qº®u医疗©xAlexandre Khaoukhov³Õ¤h评论说¡C
°£¤F¦b¯S应©Ê¥Öª¢±wªÌ¨¤W¬Ý¨ìªºµhW¡B发ª¢ªº¥Ö损¥~¡AºC©Êæ±Ö}¤]会¨Ï这Ïú¯e¯fªº¾ãÊ^负ü®变±o虚®z¡A严«损®`¥Í¬¡质¶q¡C这¨Ç数Õu´y绘¤Feblasakimab¦bú£¤Öæ±Ö}©Ê¯«经¤¸¤Ï应¤è±ªº¥O¤H¹ª»Rªº画±¡A¦}¼W¥[¤F§Ú们对eblasakimab³q过2«¬¨üÊ^对IL-4©MIL-13进¦æ双«ªý断ªº独¯S§@¥ÎÉó¨îªº²z¸Ñ¡C
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2022/5/19 ¤U¤È 08:34:17
²Ä 5314 ½g¦^À³
|
Eblasakimab may be efficacious against a wide range of AD comorbidities, such as asthma and allergy
Eblasakimab¥i¯à¹ï¼sªxªºAD¦X¨Ö¯g¦³Àø®Ä¡C ¡A¦pý³Ý©M¹L±Ó¯g¡C
p.12 ir.aslanpharma.com/static-files/20941066-3bc3-418b-a970-9951565de0f2
81% of moderate-to-severe AD patients have Type 2 inflammatory comorbidities:
¤¤«¯gAD±wªÌ,±w¦³«¬2ª¢¯gªº¨Öµo¯g81%
¨ä¤¤±w¹L±Ó©Ê»óª¢ªÌ¨Öµo¯g 50% ¨ä¤¤±w¹L±ÓªÌ¨Öµo¯g 38% ¨ä¤¤±wý³Ý¨Öµo¯g 35% ¨ä¤¤±w¹ª«¹L±Ó¨Öµo¯g 34%
Blockade of IL-4 and IL-13 signaling through the Type 2 receptor will be important to address both IL-4 and IL-13 driven comorbidities in AD patients.
Physicians would prefer treatment options that can address these other conditions.
ªýÂ_ IL-4 ©M IL-13 ³q¹L«¬ 2 µo«H¸¹¨üÅé ±N«Ü«n¥i¦P®É¸Ñ¨MAD±wªÌ¦] IL-4 ©M IL-13ÅX°Êªº¦X¨Ö¯g ¡C
Âå¥Í̧ó³ßÅw¥i¦P®ÉªvÀø¨ä¥L¦X¨Ö¯gªºÃÄ¡C
¸ê®Æ¨Ó·½: 237¦ì±wªÌªº¬ã¨s.µoªí©ó2022¦~AAD ¦~·|. Source: Calzavara-Pinton et al (2022) AAD Annual Meeting poster presentation, Baseline patient demographics and comorbidities in patients with atopic dermatitis from the GLOBOSTAD registry (237 patients) -------- µù: Dupilumab ¦¤w°µ¹LÃþ¦ü¬ã¨s.
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2022/5/19 ¤U¤È 07:03:05
²Ä 5313 ½g¦^À³
|
ir.aslanpharma.com/static-files/20941066-3bc3-418b-a970-9951565de0f2
¤½¥q²³ø---2022/05/19----§ó·s |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2022/5/19 ¤W¤È 09:24:12
²Ä 5312 ½g¦^À³
|
¥@¬ö¯«ÃÄHumiraºÙÅQ¥þ²y20¦~ 2021¦~¡A¾P°â207»õ¬ü¤¸¡A2023¦~²Ä¤@Ó¾AÀ³¯g¤W¥«¡C
2000¦~¡A¨È°ö¤½¥q¥H69»õ¬ü¤¸·m¤U¡C¡A2´Á§¹¦¨¶RÂ_¡C
21¦~¨Ó²Öp¾P°â1507»õ¬ü¤¸¡C(¨ì2017¬°¤î)¡A Yºâ¨ì2022¦~¡A¶W¹L2500»õ¬ü¤¸¡C
2023¦~¡A¥é¥ÍÃĥثe¦ô11Ó¡A¥iªÅ³°Äò¦b¬ü°ê¤W¥«¡C
®Ö¤ß±M§Q¡A2016¦~¡A¬ü°ê¨ì´Á¡A¦ý§Q¥Î100¦hÓ±M§Q¡A¥´©x¥qÅý¥é¥ÍÃĪ½¨ì2023¤~¯à¦b¬ü°ê¤W¥«¡C
¬G¨Æ¸Ô¨£¡A¦p¤U¡C
www.wealth.com.tw/articles/cfadd307-f325-494e-aad8-801766fe4c37
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¸Ø±i10133098 |
µoªí®É¶¡:2022/5/15 ¤U¤È 08:42:23
²Ä 5311 ½g¦^À³
|
·PÁ¤ѩR¤j¡AÁÙ¬O¨º¥y¸Ü¡C ¤Ñ©R¤j·Qªº¨ìªº¡A¨È·à±d©Mð¸ê¥»¸g¬ö¤½¥q¤]³£·Q¨ì¤F¡C ¨È·à±d³Ì³Ì³Ì¤@¶}©lªº¤½¶}»¡©ú®Ñ¼g±o004°²·Q¼Ä´N¬O§ùÁת¢¡C ð¸ê¥»¤½¥q·|¥h¸ò¨È·à±d«Øij¦¬®×¹ï¶H¡A¤£µM¨È·à±d§ä¿ù¯f¤H¡Að¸ê¥»¤½¥qªº§ë¸ê¤£´N¦å¥»µLÂk¡C 004ªº2b¦¬®×SOP¸òµÛ§ùÁת¢¨«¡A³Ì«áÃĮĴN¯à¤j©ó§ùÁת¢20%¥H¤W¡C (ý³Ý©M¨ä¥L¯gª¬Á{§É¸ÕÅç·ÓµÛ§ùÁת¢¨«¡A¦¨¥»¥i¥H°«Ü¤j¡A·Q¨ÖÁʪºÃļt¤]ª¾¹D) ------------------------- ½ÐÅÞ¿è«ä¦Ò
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2022/5/15 ¤U¤È 07:17:40
²Ä 5310 ½g¦^À³
|
Dupilumab 2Ó¤T´ÁÁ{§É,°ò½u¶}©l«e35¤Ñ¶¡ªº¤H¿ï¿z¿ï¥h°£²v36.3%
1.SOLO1 ,Out of 917 participants, 671 were randomized (¿z¿ï¥h°£±¼917-671=246¤H, ¥h°£²v36.6%) 2.SOLO2, Out of 962 participants, 708 were randomized (¿z¿ï¥h°£±¼962-708=254¤H, ¥h°£²v35.8%) ¤pp 1879 ¤H°Ñ¥[¿z¿ï ,1379¤H¶i¤J¤T´ÁÅç§ÉªºÀH¾÷¤À°t, ¥h°£²v(1879-1379)/1379=36.3%
Study of Dupilumab Monotherapy Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis (SOLO 1) clinicaltrials.gov/ct2/show/results/NCT02277743
Study of Dupilumab (REGN668/SAR231893) Monotherapy Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis (SOLO 2) clinicaltrials.gov/ct2/show/results/NCT02277769
SOLO1
Out of 917 participants, 671 were randomized and 669 were treated in the study.
Participants were randomized in 1:1:1 ratio to receive Dupilumab 300 mg once weekly (qw), Dupilumab 300 mg every 2 weeks (q2w) or Placebo qw
SOLO2
Recruitment Details The study was conducted in 10 countries between 03 December 2014 and 21 January 2016. A total of 962 participants were screened in the study. Pre-assignment Details Out of 962 participants, 708 were randomized and 707 were treated in the study. Participants were randomized in 1:1:1 ratio to receive Dupilumab 300 mg once weekly (qw), Dupilumab 300 mg every 2 weeks (q2w) or Placebo qw. |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2022/5/15 ¤U¤È 06:30:04
²Ä 5309 ½g¦^À³
|
dupilumab ¤T´Áp¹º
p.33~34 ¥Î35¤Ñªºªº®É¶¡¿z¿ï±wªÌ,°µ¤U¦C¨Æ³»¶µ
Screening/Baseline: Informed Consent X ICF for optional assessments2 X Inclusion/Exclusion X X Medical History/ Demographics X Randomization X Training on IVRS3 X
Efficacy: 7,8 Pruritus NRS (daily)3 X X X X X X X X X X X X X X Pruritus Categorical Scale (daily)3 X X X X X X X X X X X X X X POEM, DLQI, EQ-5D, HADS9 X X X X X X X X Patient Global Assess of Disease X X X X X X X Patient Global Assess of Treatment X X X X X IGA, EASI, GISS, SCORAD, BSA X X X X X X X X ACQ-5, SNOT-229 X
Safety:7 Weight X X Height X Vital Signs X X X X X X X X Physical Examination X Electrocardiogram X Adverse Events
Laboratory Testing:(¹êÅç«Ç¸ÕÅç) HIV ab, HBsAg, Hep C Ab, TB11 Hematology, Chemistry Urinalysis Pregnancy Test (WOCBP only) Serum Urine Urine Urine Urine TARC Total serum IgE Antigen-specific IgE sample12 hs-CRP, ANA, anti-dsDNA, antiTPO Skin microbiome samples (select sites)13
Research samples(serum/plasma)
www.nejm.org/doi/suppl/10.1056/NEJMoa1610020/suppl_file/nejmoa1610020_protocol.pdf |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¸Ø±i10133098 |
µoªí®É¶¡:2022/5/15 ¤W¤È 11:19:14
²Ä 5308 ½g¦^À³
|
¤Ñ©R¤j·Qªº¨ìªº¡A¨È·à±d©Mð¸ê¥»¸g¬ö¤½¥q¤]³£·Q¨ì¤F¡C ð¸ê¥»¤½¥q·|¥h¸ò¨È·à±d«Øij¦¬®×¹ï¶H¡A¤£µM¨È·à±d§ä¿ù¯f¤H¡Að¸ê¥»¤½¥qªº§ë¸ê¤£´N¦å¥»µLÂk¡C ------------------------- ½ÐÅÞ¿è«ä¦Ò
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2022/5/15 ¤W¤È 08:28:30
²Ä 5307 ½g¦^À³
|
³o´N¬ODupilumab¤T´Á¡A§CTRAC<1115¡A©Û¶Òªº«ÂI¡C
¥»组§C©óEASI21¡A¥B§CIgE组¡A¤T§C组¡A³Ì°ª¥u¦û3.75%¡C
³o¬ODupilumabªº©Û¶Ò±M·~¡C Á׶}¥i¯àªº«D¶Ç²ÎAD±wªÌªºµý¾Ú¡C
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2022/5/15 ¤W¤È 08:12:35
²Ä 5306 ½g¦^À³
|
§ó¥¿¡B
Dupilumab ¤T´ÁÁ{§É
1¡A¤¤Â_²v<7% 2¡A°ò½uTRAC<1115 ¬ù33%¡A¥§¡EASI约25 2.1°ò½uTRAC<1115,¥§¡EASI<25,¥u¦û16.5% ±À½×¥»组°ò½u³o´N¬Oµý¾Ú¡ADupilumab ¤T´Á°ª«×±M·~¡C Á׶}¥i¯à«D¶Ç²ÎAD±wªÌ¡C
3¡A°ò½uIgE §C²Õ¬ù15% 3.1,°ò½uIgE§C组ªº¥§¡EASI¬°25 °ò½uIgE组¥B¥§¡EASI<25¡A¥u¦û7.5% ±À½×¥»组EASI<21,¥u¦û3.75% ³o´N¬OÃÒ¾Ú¡Adupilumab¤T´Á¡A«Ü±M·~¡A«Ü·|¿z¿ï¤H¡C 4¡A°ò缐EASI<21¬ù25%
4.1±À½× °ò½uEASI<21 ¡A25%¤¤ °ªIgE 组¦û21.25% °ªTRAC组¦û16.75% §CIgE¡A§CTRAC¥B
³o´N¬ODupilumab¤T´Á¡A§CTRAC¡A©Û¶Òªº«ÂI¡C
¬Ý³ø§i¤£²`¤J¡A·|³Q»~¾Éªº¡C Fb825 2a,ASLAN004 1b,CBO201 2b ADÁ{§É¡K¡K¬Ò¦³¤j¶q«D¶Ç²ÎAD¡C
§Æ±æASLN ¤½¥q¦b2b¯à¯uªº§ïµ½¡C ¦n¦nªº¦VDupilumab ¤T´Á¾Ç²ß |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2022/5/15 ¤W¤È 07:56:56
²Ä 5305 ½g¦^À³
|
Dupilumab ¤T´ÁÁ{§É
1¡A¤¤Â_²v<7% 2¡A°ò½uTRAC<1115 ¬ù33%¡A 2.1°ò½uTRAC<1115,¥§¡EASI¬ù25, ±À½×¥»组°ò½u³o´N¬Oµý¾Ú¡ADupilumab ¤T´Á°ª«×±M·~¡C Á׶}¥i¯à«D¶Ç²ÎAD±wªÌ¡C
3¡A°ò½uIgE §C²Õ¬ù15% 3.1,°ò½uIgE§C组ªº¥§¡EASI¬°25 °ò½uIgE组¥B¥§¡EASI<25¡A¥u¦û7.5% ±À½×¥»组 ³o´N¬OÃÒ¾Ú¡Adupilumab¤T´Á¡A«Ü±M·~¡A«Ü·|¿z¿ï¤H¡C 4¡A°ò缐EASI<21¬ù25%
4.1±À½× °ò½uEASI<21 ¡A25%¤¤ °ªIgE 组¦û21.5% °ªTRAC组¦û17.5%
³o´N¬ODupilumab¤T´Á¡A§CTRAC¡A©Û¶Òªº«ÂI¡C
¬Ý³ø§i¤£²`¤J¡A·|³Q»~¾Éªº¡C Fb825 2a,ASLAN004 1b,CBO201 2b ADÁ{§É¡K¡K¬Ò¦³¤j¶q«D¶Ç²ÎAD¡C
§Æ±æASLN ¤½¥q¦b2b¯à¯uªº§ïµ½¡C ¦n¦nªº¦VDupilumab ¤T´Á¾Ç²ß¡C |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¸Ø±i10133098 |
µoªí®É¶¡:2022/5/14 ¤U¤È 10:25:33
²Ä 5304 ½g¦^À³
|
·PÁ¤ѩR¤j、¥xÁÞ¤j¸Ô²Óªº¤ÀªR©M¹w´Áªºµ²ªG¡C ð¸ê¥»§ë¸ê°òª÷¤½¥q¤]¬O¦³¸ò¨â¦ì¤j¤j¬Û¦Pªº¤ÀªR¤Î¹w´Áµ²ªG¡C ð°òª÷¤½¥q¬O¤@®a§ë¸ê¥Íª«¬ì§Þªº°òª÷¤½¥q¡A¥¦§ë¸êªº23Àɤ½¥q¸Ì±´N¬O20ÀɬO¥Íª«¬ì§Þ¤½¥q¡C 𤽥q¸u½Ðªº³£¬O¥Íª«¬ì§Þªº±M®a¾ÇªÌ¡A¯à¤O¤@©w³£¦b¤Ñ©R¤j©M¥xÁÞ¤j¤§¤W¡C ³o¨Ç±M®a¾ÇªÌ¬ã¨s§¹¡A¹ïµ²ªG¦³§â´¤¡A¤~´±«Øij¤½¥q¤j¶q¶R¶i§ë¸ê¨È·à±d(¦³¿³½ìªÌ¥i¥Hºâ¤@¤U²Ä¤@©u¥¦ªá¦h¤Ö¿ú¶R¶i)¡C
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¥xÁÞ10138776 |
µoªí®É¶¡:2022/5/14 ¤U¤È 09:44:34
²Ä 5303 ½g¦^À³
|
¤Ñ©R¤j ·PÁ¤À¨É,¤½¥qÀ³¸Ó·|ª`·NªÑªF¤ÏÀ³,©Û¶Ò³Ì¾A·íªº¨ü¸Õ , ´£°ªÁ{§É¸ÕÅ禨¥\¾÷²v ASLAN 004(AD)2b ASLAN 003 ¤G´Á (IBD )³o¨âÁû¤jÃĬO¤½¥q²æL´«°©ªº«ü¼Ð©ÊÁ{§É¸ÕÅç |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2022/5/14 ¤U¤È 09:23:23
²Ä 5302 ½g¦^À³
|
Dupilumab ¤T´ÁÁ{§É
1¡A¤¤Â_²v<7% 2¡ATRAC<1115 ¬ù33%¡A 3¡AIgE §C²Õ¬ù15% 4¡A°ò缐EASI<21¬ù25%
TRAC§C²Õ¡A<1115¡AIgE §C²Õ³Ì°ª¤ñ²v¶È¦³15%ªº¾÷·|¡A¥t¦Ü¤Ö18%¬OÄÝ©ó°ªIgG²Õ
Y§CTRAC²Õ¡A¦ý¨äIgE¬O°ª²Õ¡A«hÀø®Ä¥²°ª¡A §CIgE²Õ¡A¦ýTRAC¬O°ª²Õ¡AÀø®Ä¥ç°ª §CEASI²Õ¡A°ªTRAC©Î°ªIgE²Õ.¥çÀ³¤£¿ùÀø®Ä¡C
°ß§CTRAC/IgE/§CªºEASI ¤T§CªÌ¡A¥i¯à¬O«D¶Ç²ÎAD±Ú¸s¡C
¥H¤WÓ¤HÆ[¹î
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2022/5/14 ¤U¤È 09:06:07
²Ä 5301 ½g¦^À³
|
FB8252a ¦¬®×99¤H¡A¦¬¨ì2/3 «D¥Ø¼Ð§CIgE±wªÌ.©Ò¥H¥Dn«ü¼Ðp>5% ASLAN004 1b ¡A¦P¤@Ó¤¤¤ß¦¬9¦ì«D¶Ç²Î©ÊAD¡C CBP201 2b ,§CTRAC¡A§CEASI
¥H¤W¬Ò³Q¯ÊDupilumab ¦¬®×±M·~¡C |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2022/5/14 ¤U¤È 08:54:02
²Ä 5300 ½g¦^À³
|
1¡AFB825 2A a.¥Dnµû¦ô«ü¼Ð¤§²Îpµ²ªG¤Î²Îp¤W¤§·N¸q: (a)®Ú¾Ú°õ¦æ¥»¸ÕÅ礧°ê»ÚCRO¤½¥q´£¨Ñ¸ÕÅç¸Ñª¼§¹¾ã¼Æ¾Ú¡A¦b¥»¸ÕÅçµ²§ô«á©Ò °õ¦æ¤§©Ò¦³¨ü¸ÕªÌ¦å²G¥Í¤ÆȤÀªR¡AÅã¥Ü¦³2/3ªº¨ü¸ÕªÌ¤£²Å¦X¥Ø¼Ð±Ú¸s- ¤¤««×²§¦ì©Ê¥Ö½§ª¢(AD)¤§¥Í¤Æ«ü¼Ð¡A¦b¨â¶µÃöÁ䪺TARC(¯Ý¸¢¬¡¤Æ½Õ¸`ÁÍ ¤Æ¦]¤l)»PIgE(§K¬Ì²y³J¥ÕE)¥Í¤Æ«ü¼Ð¤W²§±`°¾§C¡A¥»¸ÕÅç2/3¨ü¸ÕªÌTARC°ò ½uȧC©ó700 pg/ml(Äv«~ÃĪ«Dupixent¦¬®×°ò½uȬ°1,953-6,147 pg/ml)¡B IgE°ò½u¥§¡È569 IU/ml(Dupixent¬°2,451-10,754 IU/ml)¡A¦]¦¹¡A§t¬A¤W z¤£²Å¦X¥Ø¼Ð±Ú¸s¨ü¸ÕªÌ«á¡A¥»¸ÕÅç¥Dnµû¦ô«ü¼ÐµLªk¹F¨ì²Îp·N¸q¡AµLªk ¶i¦æ³o¨Ç«D¥Ø¼Ð±Ú¸s¤§¨ü¸ÕªÌ¦³·N¸qµû¦ô¡C
¤@¤@¤@RITT ¤ÀªR
(b)¸g¶i¤@¨B¤ÀªR¡A©ó1/3¥Ø¼Ð±Ú¸s(TARC°ò½uȤj©ó700 pg/ml)ªºÃöÁäÀø®Ä«ü¼Ð EASI 75(²§¦ì©Ê¥Ö½§ª¢§ïµ½75%¡A¬°ÃÄ«~¤T´ÁÁ{§É¸ÕÅç¥DnÀø®Ä«ü¼Ð)¡A FB825¹F¨ì53.8%¡A¹ï·Ó²Õ¬°29.4%¡A»PÄv«~ÃĪ«Dupixentªº¨â¶µ¤T´Á¸ÕÅçµ² ªG44%¤Î51%¬Û·í¡C¤@¤@¤@¡]Dupilumab ¹ï·Ó²Õ 12%/15%) FB825©ó¥Ø¼Ð±Ú¸s¹F¨ì¹w´Á¤§¸ÕÅçªvÀø®ÄªG¡A¥i¤ä«ù¶i¦æ¡@ «áÄò¸ÕÅç¡C
2.CBP201
investors.connectbiopharm.com/events/event-details/global-phase-2b-trial-cbp-201-atopic-dermatitis-data-review-call
CBP201¤@ AD 2b ¸Ô²Ó¤ÀªRÀÉ(2022/01/05) ½Ð¦Û¦æ¤U¸ü¡C
CBP201 ©Ò¹J§x¹Ò©MASLAN 1b ¬Û¦ü¡C
1.¤¤断²v°ª约19% (Dupilumab 3´Á6%//2´Á¨ä¹ê¤]ªñ19%) ¨ä¥LLebtri/Tralo ¤]¬O¤G´Á¤¤断²v°ª约20%¡A¤T´Á¤¤断²v´N¤j°8%¥ª¥k¡C
2.CBP 201 TRAC §C²Õ (°ò½u)¡A16¶g¡«á EASI ¥§¡°´T53% TRAC ¤¤°ª组(°ò½u)¡A 63%¡K¡K2¶g¤@°wx300mg组 EASI §C组(°ò½u<18), 52%¡K¡K2¶g¤@°wx300mg组
Dupilumab TRAC §C组/EASI¥§¡25.1(°ò½u)¡A 16¶g¡«áEASI¥§¡°78%
__
«Øij¤½¥q¡A2b¡AÀ³®ÄªkDupilumab 3´Á TRAC§C组¡AEASI¥§¡¦¬¦b25
§C©óEASI20ªº¤£n¦¬¡C
¡¦¡K¡K¡K¡K¡K¡K¡K¡K¥i¯à¤j¦h«D¶Ç²ÎAD¡C
3¡AASLAN004 1b 9¦ì «D¶Ç²ÎAD°ò缐
§CTRAC¡A§CIgE¡A§CEASI19.9
4¡ADupilumab ¤T´Á¡ATRAC¤ÀªR¡A¥xÁÞ¤j¤À§é¬O¥¿½T¡C
§CTRAC¤Î§CIgE²Õ¬Ò¦³°ªÀø®Ä¡A¦ý¨ä°ò缐¥§¡¦bEASI25
ºî¦X¤Wz¡A «ØijÁ׶}TRAC¥B§CIgE¥BEASI¤p©ó21¡K¥i¯à¬O«DAD±Û¸s¡A
µ²½×°l´`Dupilumab ¤À°t§Y¥i¡A¤j¶qÁ׶}«D¶Ç²ÎAD¦Ó¦³°ª¤ô·ÇªºÀø®Ä¡C ¡A |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¥xÁÞ10138776 |
µoªí®É¶¡:2022/5/14 ¤U¤È 08:17:46
²Ä 5299 ½g¦^À³
|
¤Ñ©R¤j Dupilumab ¤T´ÁTRAC¤ÀªR www.morressier.com/o/event/5d4178148fb7e44098e72af1/article/5d4980cb8fb7e44098e72cd2
þ¸Ì¥i¬Ý¨ì¥Íª«¼Ð»xª« CCL17/TARC ©MÁ` IgE °ª§C¹ï EASI ©Mæ±Äo NRS µû¤À·|¦³©Ò¤£¦P ?
³o½g¤å³¹¼ÐÃD¤w»¡©ú Biomarkers CCL17/TARC and Total IgE Do Not Predict Clinical Response to Dupilumab in Atopic Dermatitis (AD): a Post hoc Analysis of Pooled Phase 3 Data (SOLO 1 & 2)
¥Íª«¼Ð»xª« CCL17/TARC ©MÁ` IgE ¤£¯à¹w´ú¹ï Dupilumab ªvÀø²§¦ì©Ê¥Ö½§ª¢ (AD) ªºÁ{§É¤ÏÀ³¡G
1¦b¬ã¨s¶}©l®É¡ABL CCL17 TARC¡]≤1115 pg/mL¡Fn=457¡^©Î IgE ¿@«×¡]<150 kU/L¡Fn=220¡^ªº±wªÌªº BL EASI ©Mæ±Äo NRS µû¤À¦b¼ÆȤW§C©ó CCL17 TARC°ªªº±wªÌ¡]> 4300 pg/mL¡Fn=457¡^©Î IgE ¤ô¥¡]≥150 kU/L¡Fn=1158¡^¡C
2¦b°ª¡B¤¤©Î§C BL CCL17 TARC©Î°ª©Î§C IgE ¤ô¥ªº±wªÌ¤¤¡A¨âºØ DUP ¾¯¶q¤è®×§¡ÅãµÛ°§C¤F 16 ¶g®É BL »P PBO ªº EASI ©Mæ±Äo NRS µû¤À¡]»P PBO ¬Û¤ñ¡A©Ò¦³ P<0.0001 )
Dupilumab ¦bªí¹F¬O§ÚªºÃĦ³Àø®Ä,¥Íª«¼Ð»xª« CCL17/TARC ©MÁ` IgE ¤£¯à¹w´ú¹ï Dupilumab ªvÀø²§¦ì©Ê¥Ö½§ª¢ (AD) ªºÁ{§É¤ÏÀ³
TRAC <1115 ,EASI ¥§¡°´T78% TRAC >1115 ,EASI ¥§¡°´T66% ³oªí¥Ü¦¬®× TRAC <1115 ¤ñ¸û¦n ¥i¬O»P¸Ó½g ³ø§i¬Û¥Ù¬Þ ¦b¬ã¨s¶}©l®É¡ABL CCL17 TARC¡]≤1115 pg/mL¡Fn=457¡^©Î IgE ¿@«×¡]<150 kU/L¡Fn=220¡^ªº±wªÌªº BL EASI ©Mæ±Äo NRS µû¤À¦b¼ÆȤW§C©ó CCL17 TARC°ªªº±wªÌ¡]> 4300 pg/mL¡Fn=457¡^©Î IgE ¤ô¥¡]≥150 kU/L¡Fn=1158¡^¡C
2022¦~1¤ë20¤é²³ø¤w¦³¼vÅTÁ{§ÉÀø®Äªº¦¬®×¤ÀªR, ¤½¥q¦³¸u½ÐÁ{§É±M·~¤Hû, ¦¬®×³¡¤À¤j®a¥i©ñ¤ß,¤½¥q¤£·|¥h¦¬¼vÅTÀø®Äªº¨ü¸Õ
¥H¤W¤À¨É ¶È¨Ñ°Ñ¦Ò |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2022/5/14 ¤U¤È 05:30:08
²Ä 5298 ½g¦^À³
|
Dupilumab ¤T´ÁÁ{§É
1¡A¤¤Â_²v<7% 2¡ATRAC<1115 ¬ù33%¡A 3¡AIgE §C²Õ¬ù15% 4¡A°ò缐EASI<21¬ù25%
YASLAN004 2bªº¦¬®×¤À°t¡A¦p¤WÀø®ÄÀ³·|¤£¿ù¡A´N¬Ý¤½¥q¦p¦ó°õ¦æ¤F¡C Dupilumab ¤T´Á¤§«e¡A°µ¤F¤j§åªºÁ{§É¡A©Ò¥H¯àÁ׶}«D¶Ç²ÎAD¡C
ASLAN004 ¹êÅç²Õ¦@¥|²Õx59¤H/²Õ¤Q¹ï·Ó²Õ59¤H¡A¦U²ÕPK¡C
¡X¡X¡X¡X¡X- ⋯⋯ ASLAN004 1b
¹êÅç²Õ «D¶Ç²ÎAD6¤H¡AEASI75¡×0%¡A Y¦³3¤HÀø®Ä¹FEASI75¡A«hITT¤ÀªR EASI75=¡] 11+3¡^/22=63.6% ¡Aì¥ý11¡þ22=50% ¦©°£13%ªº¹ï·Ó²Õ¡A¥i¹F¨ì50%¡Avs Dupilumab 36% ¦¹¦¨ÁZ´N¯à>dupilumab20%
3/22=13.6%¡A«DAD±wªÌªº±Ú¸s¬°³Ì§C«×¡C ì¥ýlbÁ{§É¡A 6/22=27.2%
⋯⋯⋯⋯⋯⋯⋯⋯⋯ Dupilumab ¤T´Á§CTRAC²Õ EASI75 ¦ô¦³58%ªº¤ô·Ç¡C
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2022/5/14 ¤U¤È 05:06:09
²Ä 5297 ½g¦^À³
|
Dupilumab ¤T´ÁÁ{§É
1¡A¤¤Â_²v<7% 2¡ATRAC<1115 ¬ù33%¡A 3¡AIIgE §C²Õ¬ù15% 4¡A°ò缐 YASLAN004 2bªº¦¬®×¤À°t¡A¦p¤WÀø®ÄÀ³·|¤£¿ù¡A´N¬Ý¤½¥q¦p¦ó°õ¦æ¤F¡C Dupilumab ¤T´Á¤§«e¡A°µ¤F¤j§åªºÁ{§É¡A©Ò¥H¯àÁ׶}«D¶Ç²ÎAD¡C
ASLAN004 ¹êÅç²Õ¦@¥|²Õx59¤H/²Õ¤Q¹ï·Ó²Õ59¤H¡A¦U²ÕPK¡C
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¸Ø±i10133098 |
µoªí®É¶¡:2022/5/14 ¤U¤È 03:41:31
²Ä 5296 ½g¦^À³
|
295Ó¦¬ªv¯f±w,¦©°£2¦¨µLªk§¹¦¨2bÁ{§É¸ÕÅç,³Ñ236¦W¯f±w¡C §Ú¤ñ¸û·Q½Ð±M·~¤Ñ©R¤j¤j³Â·Ð¤ÀªRªº¬O, ¥H004ÃÄ®ÄŧùÁת¢20%ªº«e´£¤U, ³Ì«O¦u¯à®e§Ô¦¬¨ì¥i¯à¬°«D¶ÇAD¯f±w¬O´XÓ?? (»~¦¬¨ì36Ó¥i¯à¬°«D¶ÇADªº¯f±w,004ªºÃÄ®ÄÁÙ¯àŧùÁת¢20%¶Ü??) ³Â·Ð¤Ñ©R¤j¤j¸Ñ´b,·P¿E¤£ºÉ¡C
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¸Ø±i10133098 |
µoªí®É¶¡:2022/5/14 ¤U¤È 03:21:51
²Ä 5295 ½g¦^À³
|
ÅÞ¿è«ä¦Ò ¤Þ¥Î¤Ñ©R¤j¤j¸Ü ASLAN004 2b ¿éŦb±wªÌ筛¿ï¡I
°ò½u TRAC>1115ªÌ¡A¬°¤j¸É¡A¡«á¥§¡Àø®Ä°ª
TRAC<1115ªÌ¥BIgE¬°§C¸¨组ªÌ¡A¬°负¤À(¥i¯à¬°«D¶ÇAD) 7RAC<1115ªÌ¥BEASI>25ªÌ¬°¤j¤j¸É¡AÀø®Ä³Ì°ª¡C
¤½¥q¦³¦h¦ìÁ{§É±M®a¡A¦¹¦¸À³¯àÁ׶}©Î°§C¤ñ²v¡C --------------------------------------------------- ³s¤Ñ©R¤j¤j³£ª¾¹DÁ׶}þ¨Ç±wªÌ¤£n¦¬¤F, ¨È·à±d¾iªº±M®a¾ÇªÌ·|²Â¨ì¥h¦¬¶Ü? (½ÐÅÞ¿è«ä¦Ò¤@¤U) |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G³¯¤p©ú10152293 |
µoªí®É¶¡:2022/5/13 ¤U¤È 06:28:05
²Ä 5294 ½g¦^À³
|
¤Ñ©R¤j
·PÁ±zªº¦^ÂÐ
ÁŵM¶}®Ô |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2022/5/13 ¤U¤È 05:34:24
²Ä 5293 ½g¦^À³
|
ASLAN004 2b ¿éŦb±wªÌ筛¿ï¡I
°ò½u TRAC>1115ªÌ¡A¬°¤j¸É¡A¡«á¥§¡Àø®Ä°ª
TRAC<1115ªÌ¥BIgE¬°§C¸¨组ªÌ¡A¬°负¤À(¥i¯à¬°«D¶ÇAD) 7RAC<1115ªÌ¥BEASI>25ªÌ¬°¤j¤j¸É¡AÀø®Ä³Ì°ª¡C
¤½¥q¦³¦h¦ìÁ{§É±M®a¡A¦¹¦¸À³¯àÁ׶}©Î°§C¤ñ²v¡C
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2022/5/13 ¤U¤È 05:14:19
²Ä 5292 ½g¦^À³
|
ASLAN004 2b ¿éŦb±wªÌ筛¿ï¡I
°ò½u TRAC>1115ªÌ¡A¬°¤j¸É¡A¡«á¥§¡Àø®Ä°ª TRAC<1115ªÌ¥BIgE¬°§C¸¨组ªÌ¡A¬°负¤À(¥i¯à¬°«D¶ÇAD)
¤½¥q¦³¦h¦ìÁ{§É±M®a¡A¦¹¦¸À³¯àÁ׶}©Î°§C¤ñ²v¡C
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2022/5/13 ¤U¤È 04:27:07
²Ä 5291 ½g¦^À³
|
www.morressier.com/o/event/5d4178148fb7e44098e72af1/article/5d4980cb8fb7e44098e72cd2
Dupilumab ¤T´ÁTRAC¤ÀªR¡C
³¯¤j¡A
µL»~¡C |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G³¯¤p©ú10152293 |
µoªí®É¶¡:2022/5/13 ¤U¤È 03:49:34
²Ä 5290 ½g¦^À³
|
-¤Ñ©R¤j
³o¤@¬q¬Ý¤£À´¡A¦³»~¶Ü TRAC <1115 ,EASI ¥§¡°´T78% TRAC >1115 ,EASI ¥§¡°´T66% |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2022/5/13 ¤U¤È 01:49:50
²Ä 5289 ½g¦^À³
|
ASLAN004 1b VS Dupilumab ph3
¤@.ASLAN004*8 ¶g *1b N=22+16¤H(ITT)
EASI75 ¹êÅç²Õ50%/¹ï·Ó²Õ13% -----ITT¤ÀªR
¹êÅç²Õ EASI75------¤À²Õ¤ÀªR A.¤¤Â_ N=13.6%(3/22) , EASI75=0%(0/3) B.TRAC <1115,°ò½uEASI=19.9, N=27.3%(6/22), EASI75= 0%(0/6)----------(¥»²Õ6¤H¬Ò«D¶Ç²ÎAD,ªvÀø©M¹ï·Ó²ÕµL®t²§,0%¹FEASI75)
C.TRAC >1115 °ò½uEASI=30.5,N=59%(13/22) , EASI75=85%(11/13)
----------------------------------------------- ¤pp N=100%(22/22), EASI75=50%(11/22 )------
¤G.Dupilumab*16¶g,P3*2 ,N=900+450 ¤H
EASI75 ¹êÅç²Õ48.5%/¹ï·Ó²Õ14% --ITT¤ÀªR
¹êÅç²Õ EASI75------¤À²Õ¤ÀªR
A.¤¤Â_ N=6.3% ,¦ôEASI75= 0% B.TRAC <1115 ,°ò½uEASI=25 ,N=30.7%, ¦ô EASI75=58% (48.5%*(78%/70%)/93.7%)=58% (¨Ì¥§¡°´T¤ñ²v¦ô/¤¤Â_²v) C.TRAC >1115 ,°ò½uEASI=36(31/41) N=62.5%,
¦ô EASI75=49%(49%*(66%/70%)/93.7%)=49%
¤pp N=100% , EASI75=48.5%
------------------------------------------ TRAC <1115 ,EASI ¥§¡°´T78% TRAC >1115 ,EASI ¥§¡°´T66%
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¸Ø±i10133098 |
µoªí®É¶¡:2022/5/13 ¤U¤È 12:42:15
²Ä 5288 ½g¦^À³
|
Dupilumab¤ÎASLAN004 ¬Ò¥i¦P®ÉªýÂ_IL4¤ÎIL13 °T®§¶Ç¾É¸ô®|¡C Lebrikizumab ¤Î Tralokinumab MOA¡A¥u¯àªýÂ_IL13 °T¸¹¶Ç»¼¡AµLªk§¹¥þªýÂ_IL4 °T¸¹¶Ç»¼¡A¥\¯à¤j´î¡C ©Ò¥HASLAN004 Àø®Ä¤j©ó©Îµ¥©óDUPILUMAB ¡A¤£¥i¯à¤ñDUPILUMAB ®t¡C ¦A¥[¤W¨ä¥L¦õÃÒ¸ê®Æ¡C
½Ð±Ð±M·~ªº¤Ñ©R¤j¤j¡A¨Ì±zªº±M·~¡G ASLAN004 Àø®Ä¤j©óDUPILUMAB ÁÙ¬O ASLAN004 Àø®Äµ¥©óDUPILUMAB ªº¾÷·|¤j??? |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G©t¨àÃÄ10140658 |
µoªí®É¶¡:2022/5/12 ¤U¤È 11:15:28
²Ä 5287 ½g¦^À³
|
²{¦b»¡ªÅ·N¸q¤w¸g¤£¤j¡A¤j®a´Á¬ß©_ÂÝ°Á{§a!!!!
©_Âݤ@:2022-2Hµoªí1B¸ÕÅ穵¦ù¦Ü16¶g¼Æ¾Ú§¹³Ó§ù¥²ª¢¡C ©_ÂݤG:2022¦~©³2B´Á¤¤¼Æ¾Ú§¹³Ó§ù¥²ª¢¡A°Æ§@¥Î»·§C©ó§ù¥²ª¢¡C ©_ÂݤT:©ú¦~¤@¤ë¬Ý¨ì¥«È¤Q»õ¬üª÷¡C
¥H¤W¹I·Q¡A§Æ±æ³v¤@¦¨¯u~~~~~~~~ |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G³¯¤p©ú10152293 |
µoªí®É¶¡:2022/5/12 ¤U¤È 10:07:17
²Ä 5286 ½g¦^À³
|
¸m©ó¦º¦a¦Ó«á¥Í
¦ý«D¦º¦Ó´_¥Í |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G«Ó°¶10144972 |
µoªí®É¶¡:2022/5/12 ¤U¤È 07:28:17
²Ä 5285 ½g¦^À³
|
©ú¤Ñ¤j±z´N¤£nÄ~Äò°l±þ¡A¤j®a³£¦³Ãz±¼ªº¤ß²z·Ç³Æ¤F°Õ ¤@±i¤£½æ¡A©_ÂݦۨӡA³»¦hÃz±¼¡A¦º¦a«á¥Í |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G©ú¤Ñ¹L«á10151242 |
µoªí®É¶¡:2022/5/12 ¤U¤È 06:54:51
²Ä 5284 ½g¦^À³
|
¤§«e¸u½Ðªº¤é¥»¤H¡A³£¤w¸gÂ÷¾¡A´N¬O¬Ý¨ì¤°»ò¿ß¿°¤~·|Â÷¥h¡AÂ÷¾«áªGµM¤@ª½¶^˲{¦b¡Aµ¥¨È·à±d¤U¥«¡A¤~·|ª¾¹Dì¨Ó¬O¹Ú¤@³õ |
|
¡@ |
¦^°Q½×°Ï1¶ |
<< 1301 ~ 1400 «h¦^ÂÐ >> |